Committee for Risk Assessment

RAC

Annex 1
Background document
to the Opinion proposing harmonised classification and labelling at EU level of

Hexyl salicylate

EC Number: 228-408-6
CAS Number: 6259-76-3

CLH-O-0000007103-85-01/F

The background document is a compilation of information considered relevant by the dossier submitter or by RAC for the proposed classification. It includes the proposal of the dossier submitter and the conclusion of RAC. It is based on the official CLH report submitted to consultation. RAC has not changed the text of this CLH report but inserted text which is specifically marked as 'RAC evaluation'. Only the RAC text reflects the view of RAC.

Adopted

18 March 2022

P.O. Box 400, FI-00121 Helsinki, Finland | Tel. +358 9 686180 | Fax +358 9 68618210 | echa.europa.eu

[04.01-ML-009.02]

CLH report

Proposal for Harmonised Classification and Labelling

Based on Regulation (EC) No 1272/2008 (CLP Regulation),
Annex VI, Part 2

International Chemical Identification: Hexyl salicylate

EC Number: **228-408-6**

CAS Number: **6259-76-3**

Index Number: **-**

Contact details for dossier submitter:

ANSES (on behalf of the French MSCA)

14 rue Pierre et Marie Curie

F-94701 Maisons-Alfort Cedex

classification.clp@anses.fr

Version number: 02 **Date: December 2020**

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON HEXYL SALICYLATE

CONTENTS

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON HEXYL SALICYLATE

1 IDENTITY OF THE SUBSTANCE

1.1 Name and other identifiers of the substance

Table 1: Substance identity and information related to molecular and structural formula of the substance

Name(s) in the IUPAC nomenclature or other international chemical name(s)	Hexyl 2-hydroxybenzoate
Other names (usual name, trade name, abbreviation)	Hexyl salicylate Benzoïc acid, 2-hydroxy-, 2-hexyl ester Salicylic acid, hexylester Hexyl *o*-hydroxybenzoate
ISO common name (if available and appropriate)	-
EC number (if available and appropriate)	228-408-6
EC name (if available and appropriate)	Hexyl salicylate
CAS number (if available)	6259-76-3
Other identity code (if available)	-
Molecular formula	$C_{13}H_{18}O_3$
Structural formula	
SMILES notation (if available)	CCCCCCOC(=O)C1=C(O)C=CC=C1
Molecular weight or molecular weight range	222.28 g/mol
Information on optical activity and typical ratio of (stereo) isomers (if applicable and appropriate)	NA
Description of the manufacturing process and identity of the source (for UVCB substances only)	NA
Degree of purity (%) (if relevant for the entry in Annex VI)	≥98%, ≤100% (mono-constituent)

1.2 Composition of the substance

Table 2: Constituents (non-confidential information)

Constituent (Name and numerical identifier)	**Concentration range (% w/w minimum and maximum in multi-constituent substances)**	**Current CLH in Annex VI Table 3.1 (CLP)**	**Current self-classification and labelling (CLP)**
Hexyl salicylate	≥98%	None	Skin Irrit. 2 – H315 Eye Irrit. 2 – H319 Skin Sens. 1 – H317 Skin Sens. 1B –H317 STOT SE 3 – H335 Aquatic Acute 1 – H400 Aquatic Chronic 1 – H410 Aquatic Chronic 2 – H411

2 PROPOSED HARMONISED CLASSIFICATION AND LABELLING

2.1 Proposed harmonised classification and labelling according to the CLP criteria

Table 3:

	Index No	International Chemical Identification	EC No	CAS No	Classification		Labelling			Specific Conc. Limits, M-factors	Notes
					Hazard Class and Category Code(s)	Hazard statement Code(s)	Pictogram, Signal Word Code(s)	Hazard statement Code(s)	Suppl. Hazard statement Code(s)		
Current Annex VI entry	No existing Annex VI entry										
Dossier submitters proposal	To be determined	Hexyl salicylate	228-408-6	6259-76-3	Skin Sens. 1 Repr. 2	H317 H361d	GHS07 GHS08 Warning	H317 H361d			
Resulting Annex VI entry if agreed by RAC and COM	To be determined	Hexyl salicylate	228-408-6	6259-76-3	Skin Sens. 1 Repr. 2	H317 H361d	GHS07 GHS08 Warning	H317 H361d			

Table 4: Reason for not proposing harmonised classification and status under public consultation

Hazard class	Reason for no classification	Within the scope of public consultation
Explosives	data conclusive but not sufficient for classification	Yes
Flammable gases (including chemically unstable gases)	hazard class not applicable	No
Oxidising gases	hazard class not applicable	No
Gases under pressure	hazard class not applicable	No
Flammable liquids	data conclusive but not sufficient for classification	Yes
Flammable solids	hazard class not applicable	No
Self-reactive substances	data conclusive but not sufficient for classification	Yes
Pyrophoric liquids	data conclusive but not sufficient for classification	Yes
Pyrophoric solids	hazard class not applicable	No
Self-heating substances	hazard class not applicable	No
Substances which in contact with water emit flammable gases	data conclusive but not sufficient for classification	Yes
Oxidising liquids	data conclusive but not sufficient for classification	Yes
Oxidising solids	hazard class not applicable	No
Organic peroxides	data conclusive but not sufficient for classification	Yes
Corrosive to metals	data conclusive but not sufficient for classification	Yes
Acute toxicity via oral route	hazard class not assessed in this dossier	No
Acute toxicity via dermal route	hazard class not assessed in this dossier	No
Acute toxicity via inhalation route	hazard class not assessed in this dossier	No
Skin corrosion/irritation	hazard class not assessed in this dossier	No
Serious eye damage/eye irritation	hazard class not assessed in this dossier	No
Respiratory sensitisation	hazard class not assessed in this dossier	No
Skin sensitisation	**harmonised classification proposed: Skin Sens 1 – H317**	Yes
Germ cell mutagenicity	hazard class not assessed in this dossier	No
Carcinogenicity	hazard class not assessed in this dossier	No
Reproductive toxicity	**harmonised classification proposed: Repro 2 – H361d**	Yes
Specific target organ toxicity-single exposure	hazard class not assessed in this dossier	No
Specific target organ toxicity-repeated exposure	hazard class not assessed in this dossier	No
Aspiration hazard	hazard class not assessed in this dossier	No
Hazardous to the aquatic environment	hazard class not assessed in this dossier	No
Hazardous to the ozone layer	hazard class not assessed in this dossier	No

3 HISTORY OF THE PREVIOUS CLASSIFICATION AND LABELLING

There is no current harmonised classification for hexyl salicylate (HS).

For information, hexyl salicylate was assessed by the Netherlands in the framework of the CoRAP (rolling plan 2012). Regarding the human health hazard assessment and related classification and labelling, the Netherlands concluded in its conclusion document dated on 2018 that information is sufficient for a proposal for harmonised classification and labelling for hexyl salicylate as Repr. 2; H361d (suspected of damaging the unborn child), which is based on a RAC (2016) opinion for salicylic acid, the main metabolite of hexyl salicylate.

RAC general comment

Hexyl salicylate is used as a fragrance ingredient in a wide range of products, including household cleaners, cosmetics, and personal care products. It does not have an entry in Annex VI to the CLP Regulation. It has been assessed in the framework of CoRAP by the Dutch competent authority that identified a need to classify hexyl salicylate as reproductive toxicant and skin sensitiser.

The dossier submitter (DS) initially proposed a read-across approach for the reproductive toxicity endpoint using salicylic acid (SA), sodium salicylate (NaS), and methyl salicylate (MeS) as source substances since no studies with hexyl salicylate are available for this endpoint. According to the DS, this read-across approach is adequate based on the assumption that hexyl salicylate like NaS and MeS are likewise metabolised to SA. The DS based this on one *in vitro* study dealing with the absorption and metabolism after application of hexyl salicylate on human skin explants.

During consultation on the dossier, one MSCA questioned the proposed read-across since no experimental data were available from other tissues than skin and no conclusion could be drawn on the metabolism of hexyl salicylate in other organs, e.g. in the liver. They also pointed out that hexyl salicylate and MeS differ considerably in their physico-chemical properties. Additionally, an industry comment on behalf of the registrants for hexyl salicylate requested clarification why data for two other possible read-across candidates, i.e. benzyl salicylate (BzS) and cyclohexyl salicylate (CHS), were not considered in the CLH report.

A targeted consultation was launched to gather additional information.

All additional information provided are included in this document in the Reproductive Toxicity section.

Available ADME data

Dermal absorption of salicylates

Based on physico-chemical properties Watkinson *et al.* (1992, *apud* Belsito *et al.* 2007) calculated dermal bioavailability of about 2.3 % for MeS (MS). Much lower dermal absorption rates were calculated for butyl salicylate (BtS) (0.068 %), pentyl salicylate (PtS) (0.017 %), hexyl salicylate (HS) (0.005 %), and ethyl hexyl salicylate (EHS) (0.0006 %).

Ethyl Hexyl salicylate

Bury *et al.* (2019) calculated that 3.0 % (mean) of a dermally applied EHS dose was absorbed from a sun screen product (based on data for specific metabolites, see below). In an *in vitro* dermal bioavailability study using human excised and skin samples from six donors, 1.82 ± 1.5 % of the topically applied dose of 1 % EHS in body lotion were recovered in the receptor fluid and the epidermis and dermis layers of the skin after 24 hours (data from an unpublished study cited in Bury *et al.* 2019). These data indicate a higher absorption rate than was calculated based on physico-chemical properties. This might be explained by the fact that test substances were applied in form of skin care products (sun screen and body lotion) that could facilitate skin penetration.

Hexyl salicylate

One *in vitro* dermal absorption and metabolism study in human skin explants is available. In the absorption part of the study, radio-labelled hexyl salicylate was applied to breast or abdomen split-thickness skin explants from four female donors at concentrations of 0.1, 20, or 100 %. Most of the applied radioactivity was washed off after 8 hours (exposure termination). After 24 hours, very small amounts of hexyl salicylate of up to 1 % were detected in the receptor fluid. In a separate metabolism phase, 0.1 % of ^{14}C-radiolabelled hexyl salicylate in dipropylene glycol was applied to breast or abdomen skin membranes (n=3) from two female donors using static diffusion cells and tissue culture medium as receptor fluid. Analysis of the receptor fluid showed an absence of hexyl salicylate, but identified SA as the major component (92.8-97.8 %, similar in both donors), indicating metabolism of hexyl salicylate by dermal esterases. Analysis of skin extracts showed variable amounts of SA and hexyl salicylate between the two donors: While for one donor, SA accounted for 86.6 to 89.3 % and hexyl salicylate for 5.7 to 10.7 % of compounds found, in the other donor percentages where 59.4 to 77.9 % and 20 to 37.4 % for SA and hexyl salicylate, respectively.

Interestingly, the DS noted one important limitation for this study that was performed according to OECD TG 428: The results for relevant reference chemicals were not made available to demonstrate the performance and reliability of the test system in the performing laboratory.

2-ethylhexyl salicylate metabolism in humans

Bury and coworkers aimed to identify specific urinary metabolites of EHS as biomarkers of oral exposure in humans (Bury *et al.* 2019). They did not use a radio-labelled compound but concentrated on characterization and measurement of metabolites that can be unequivocally attributed to EHS exposure (2-ethyl-5-hydroxyhexyl 2-hydroxybenzoate (5OH-EHS), 2-ethyl-5-oxohexyl 2-hydroxybenzoate (5oxo-EHS), and 5-(((2-hydroxybenzoyl)oxy) methyl)heptanoic acid (5cx-EPS)). In the course of their study, they found SA and salicyluric acid (SUA), another metabolite downstream of the SA metabolic pathway, in urine samples of orally exposed individuals. No numeric data are available in the publication. For SUA, concentrations were described as "rather high". However, the authors acknowledged that apart from EHS, other salicylic acid esters, that are frequently used as fragrance ingredients, and acetyl salicylic acid used as analgesic drug can also be expected to be metabolised extensively to SA. Thus, the source of neither SA nor SUA was identified in this study but can be assumed to be partially related to EHS.

Cyclohexyl and benzyl salicylates

No experimental toxicokinetic data for cyclohexyl and benzyl salicylates were provided with the REACH registration dossiers for these substances. Additional data were not provided by industry. Therefore, RAC decided to exclude these substances from the read-across approach.

Esterases

In an extensive review on human esterases, Lockridge and Quinn (2010) reported that in humans, liver carboxylesterase (CES1) and the carboxylesterase in the small intestine (CES2) have different substrate specificities. While CES1 preferentially hydrolyzes esters with a small alcohol group and a large acyl group; CES2 preferentially hydrolyzes esters with a large alcohol group. In that review, they provided cocaine and the hydrolysis of its methyl ester bond as example for the former and cocaine benzoyl ester as example for the latter. Thus, it can be assumed that similarly salicylate esters with various alcohol moieties might be metabolised by one (or both) of these enzymes.

Furthermore, differences in esterase distribution have been reported between humans and rodents with rodents expressing carboxyl esterases in their blood while humans do not (Li *et al.* 2005 *apud* Lockridge and Quinn 2010).

These differences in the site of metabolism for different salicylates together with inter-species differences in carboxyl esterases expression should be considered in the proposed read-across.

4 JUSTIFICATION THAT ACTION IS NEEDED AT COMMUNITY LEVEL

There is no requirement for justification that action is needed at Community level for classifying as reprotoxic. The harmonised classification and labelling of the main metabolite of hexyl salicylate, salicylic acid, is Repr. 2; H361d (suspected of damaging the unborn child). Based on a rapid and assumed complete hydrolysis of hexyl salicylate into salicylic acid, it justifies a harmonised classification and labelling according to article 36 of CLP for hexyl salicylate.

Concerning classification for skin sensitisation, justification that action is needed at Community level is required.

Differences in self-classification

Inconsistent self-classifications for skin sensitisation are reported in the ECHA inventory database. C&L Inventory (checked on 14th April 2020) reported that:

- 1829/1884 notifiers classify hexyl salicylate as Skin Sens. 1 – H317;

- 23/1884 notifiers classify hexyl salicylate as Skin Sens. 1B – H317 (lead dossier of the REACH registration joint submission).

- 32/1884 notifiers do not classify hexyl salicylate for its skin sensitisation properties

Finally, considering the identified uses of hexyl salicylate (especially in washing and cleaning products), an action at Community level is judged needed regarding classification as skin sensitiser.

5 IDENTIFIED USES

Hexyl salicylate is a fragrance ingredient used in many fragrance compounds. It may be found in fragrances used in decorative cosmetics, fine fragrances, shampoos, toilet soaps and other toiletries as well as in non-cosmetic products such as household cleaners and detergents (Lapczynski *et al*. 2007).

According to ECHA website, the substance is manufactured and/or imported in the European Economic Area in 1 000 - 10 000 tonnes per year. This substance is used by consumers, by professional workers (widespread uses) and by industrial workers. It is used to formulate mixtures and as an intermediate to manufacture other products. This substance is used in the following products: air care products, washing & cleaning products, cosmetics and personal care products, biocides (e.g. disinfectants, pest control products), polishes and waxes, perfumes and fragrances (ECHA website, 2020).

6 DATA SOURCES

Information described in this CLH report are based on the REACH registration dossier, the Substance Evaluation Conclusion and Evaluation Report submitted by the Netherlands, the CLH reports of methyl salicylate and salicylic acid and bibliographic research (March – April 2020).

7 PHYSICOCHEMICAL PROPERTIES

Table 5: Summary of physicochemical properties

Property	Value	Reference	Comment (e.g. measured or estimated)
Physical state at 20°C and 101,3 kPa	Colourless liquid	SEv Report, July 2018 (NL)	Visual inspection
Melting/freezing point	269 ± 0.5 K (-4 °C)	SEv Report, July 2018 (NL)	Measured
Boiling point	571 ± 0.5 K (298 °C) at 100.62 kPa	SEv Report, July 2018 (NL)	Measured
Relative density	1.038 g/mL at 20 °C	SEv Report, July 2018 (NL)	Measured
Vapour pressure	7.7 10^{-5} kPa at 23 °C	SEv Report, July 2018 (NL)	Measured
Surface tension	Not determined	SEv Report, July 2018 (NL)	Study scientifically unjustified
Water solubility	2 mg/L at 23 °C	SEv Report, July 2018 (NL)	Measured
Partition coefficient n-octanol/water	Log P_{ow} = 5.5	SEv Report, July 2018 (NL)	Measured
Flash point	151 °C	SEv Report, July 2018 (NL)	Measured
Flammability	Not flammable	SEv Report, July 2018 (NL)	Concluded from flash point value
Explosive properties	Not explosive	SEv Report, July 2018 (NL)	Statement
Self-ignition temperature	251 °C at 1013 hPa	SEv Report, July 2018 (NL)	Measured
Oxidising properties	Not classified	SEv Report, July	Statement

Property	Value	Reference	Comment (e.g. measured or estimated)
		2018 (NL)	
Granulometry	Not applicable	SEv Report, July 2018 (NL)	-
Stability in organic solvents and identity of relevant degradation products	Not critical	SEv Report, July 2018 (NL)	Statement
Dissociation constant	Not applicable	SEv Report, July 2018 (NL)	Statement
Viscosity	10 mPa.s at 25 °C (dynamic)	SEv Report, July 2018 (NL)	Measured

8 EVALUATION OF PHYSICAL HAZARDS

8.1 Explosives

Table 6: Summary table of studies on explosive properties

Method	Results	Remarks	Reference
Statement	Not classified for explosive properties	-	SEv Report

8.1.1 Short summary and overall relevance of the information provided on explosive properties

Hexyl salicylate does not contain any groups associated with explosivity. Explosive properties are associated with the presence of certain chemical groups in a molecule which can react to produce very rapid increases in temperature or pressure. When there are no chemical groups associated with explosive properties present in the molecule then a substance or mixture shall not be classified as explosive.

8.1.2 Comparison with the CLP criteria

A statement based on the chemical structure of the substance is acceptable.

8.1.3 Conclusion on classification and labelling for explosive properties

Not classified for explosive properties.

8.2 Flammable gases (including chemically unstable gases)

8.2.1 Short summary and overall relevance of the provided information on flammable gases (including chemically unstable gases)

Not applicable as the substance is a liquid.

8.2.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.2.3 Conclusion on classification and labelling for flammable gases

Not classified as flammable gas.

8.3 Oxidising gases

8.3.1 Short summary and overall relevance of the provided information on oxidising gases

Not applicable as the substance is a liquid.

8.3.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.3.3 Conclusion on classification and labelling for oxidising gases

Not classified as oxidising gas.

8.4 Gases under pressure

8.4.1 Short summary and overall relevance of the provided information on gases under pressure

Not applicable as the substance is a liquid.

8.4.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.4.3 Conclusion on classification and labelling for gases under pressure

Not classified as gas under pressure.

8.5 Flammable liquids

Table 7: Summary table of studies on flammable liquids

Method	Results	Remarks	Reference
Flash point measurement	151 °C at 1013 hPa Not classified as flammable liquid	Purity of the test item was not reported	SEv Report

8.5.1 Short summary and overall relevance of the provided information on flammable liquids

A flash point of 151 ºC was recorded for hexyl salicylate. As hexyl salicylate is not a gas oil, diesel, light heating oil with flash point up to 75°C or a halogenated substance, mixture containing halogenated, volatile or non volatile flammable substance, it should not be subject to hazard class ‘flammable liquid’.

8.5.2 Comparison with the CLP criteria

Not classified as flammable liquid considering its flash point.

8.5.3 Conclusion on classification and labelling for flammable liquids

Not classified as flammable liquid.

8.6 Flammable solids

8.6.1 Short summary and overall relevance of the provided information on flammable solids

Not applicable as the substance is a liquid.

8.6.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.6.3 Conclusion on classification and labelling for flammable solids

Not classified as flammable solid.

8.7 Self-reactive substances

Table 8: Summary table of studies on self-reactivity

Method	Results	Remarks	Reference
Statement	Not classified as self-reactive substance	-	SEv Report

8.7.1 Short summary and overall relevance of the provided information on self-reactive substances

Hexyl salicylate does not contain any groups associated with self-reactivity. Self-reactive properties are associated with the presence of certain chemical groups in a molecule which can react to produce very rapid increases in temperature or pressure. When there are no chemical groups associated with self-reactive properties present in the molecule then a substance or mixture shall not be classified as self-reactive.

8.7.2 Comparison with the CLP criteria

A statement based on the chemical structure of the substance is acceptable.

8.7.3 Conclusion on classification and labelling for self-reactive substances

Not classified as self-reactive substance.

8.8 Pyrophoric liquids

Table 9: Summary table of studies on pyrophoric liquids

Method	Results	Remarks	Reference
Statement	Not classified as pyrophoric liquid	-	SEv Report

8.8.1 Short summary and overall relevance of the provided information on pyrophoric liquids

Experience of handling and manufacturing shows that hexyl salicylate does not spontaneously ignite at ambient temperature when exposed to air.

8.8.2 Comparison with the CLP criteria

8.8.3 No experimental test is necessary when there is a sufficient knowledge and experience of the substance to consider that it is not pyrophoric.Conclusion on classification and labelling for pyrophoric liquids

Not classified as pyrophoric liquid.

8.9 Pyrophoric solids

8.9.1 Short summary and overall relevance of the provided information on pyrophoric solids

Not applicable as the substance is a liquid.

8.9.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.9.3 Conclusion on classification and labelling for pyrophoric solids

Not classified as pyrophoric solid.

8.10 Self-heating substances

8.10.1 Short summary and overall relevance of the provided information on self-heating substances

Not applicable as the substance is a liquid.

8.10.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.10.3 Conclusion on classification and labelling for self-heating substances

Not classified as self-heating substance.

8.11 Substances which in contact with water emit flammable gases

Table 10: Summary table of studies on substances which in contact with water emit flammable gases

Method	Results	Remarks	Reference
Solubility in water	2 mg/L at 23 °C	No emission of gas was reported when	SEv Report

Method	Results	Remarks	Reference
		the substance was dissolved in water	

8.11.1 Short summary and overall relevance of the provided information on substances which in contact with water emit flammable gases

No reaction is observed when the substance is diluted in water.

8.11.2 Comparison with the CLP criteria

Not necessary if experience in handling shows that the substance does not react with water.

8.11.3 Conclusion on classification and labelling for substances which in contact with water emit flammable gases

Not classified as substance which in contact with water emits flammable gases.

8.12 Oxidising liquids

Table 11: Summary table of studies on oxidising liquids

Method	Results	Remarks	Reference
Statement	Not classified as oxidising liquid	-	SEv Report

8.12.1 Short summary and overall relevance of the provided information on oxidising liquids

Considering the structural environment of oxygen in the molecule and the oxygen balance of hexyl salicylate (CAS: 6259-76-3), it can be concluded, beyond reasonable doubt, that hexyl salicylate (CAS: 6259-76-3) is unlikely to be an oxidizer and will be incapable of reacting exothermically with combustible materials. It needs not be tested experimentally for oxidizing properties.

8.12.2 Comparison with the CLP criteria

Test is not necessary as oxygen atoms are chemically bonded only to carbons and hydrogens.

8.12.3 Conclusion on classification and labelling for oxidising liquids

Not classified as oxidising liquid.

8.13 Oxidising solids

8.13.1 Short summary and overall relevance of the provided information on oxidising solids

Not applicable as the substance is a liquid.

8.13.2 Comparison with the CLP criteria

Not applicable as the substance is a liquid.

8.13.3 Conclusion on classification and labelling for oxidising solids

Not classified as oxidising solid.

8.14 Organic peroxides

8.14.1 Short summary and overall relevance of the provided information on organic peroxides

Hexyl salicylate is not classified as an organic peroxide as defined by its molecular structure.

8.14.2 Comparison with the CLP criteria

The substance does not contain any organic peroxide in its molecular structure.

8.14.3 Conclusion on classification and labelling for organic peroxides

Not classified as organic peroxide.

8.15 Corrosive to metals

Table 12: Summary table of studies on the hazard class corrosive to metals

Method	Results	Remarks	Reference
Statement	Not classified as corrosive to metals	Although no waiver is explicitly mentioned in CLP regulation, the statement is considered acceptable considering the chemical structure of the substance	SEv Report

8.15.1 Short summary and overall relevance of the provided information on the hazard class corrosive to metals

The substance does not contain any halogen atom, has neither acidic nor alkaline functional groups, and is not known to form complexes with metals.

8.15.2 Comparison with the CLP criteria

Although no waiver is explicitly mentioned in CLP regulation, the rationale above is sufficiently convincing considering the experience of handling of the substance.

8.15.3 Conclusion on classification and labelling for corrosive to metals

Not classified as corrosive to metals.

RAC evaluation of physical hazards

Summary of the Dossier Submitter's proposal

The DS proposed no classification for all physical hazards, based on test results and the results of the screening procedure relevant for each hazard class.

Comments received during consultation

No comments were received.

Assessment and comparison with the classification criteria

Hexyl salicylate is a liquid, therefore hazard classes for gases and solids do not apply.

Hexyl salicylate does not contain any molecular structures associated with explosive properties, self-reactive properties and no peroxide or acidic moieties. Thus, it does not fulfil screening criteria for explosives, self-reactive substances, organic peroxides, and corrosive to metals.

The substance has a flash point of 151°C at 1013 hPa, therefore it does not fulfil the criteria for classification as flammable liquid.

Based on handling and manufacturing experience, hexyl salicylate is not a pyrophoric liquid, does not emit flammable gases upon contact with water.

Hexyl salicylate contains only oxygen atoms bound to hydrogens or carbons, thus it doesn't have oxidising properties.

Thus, RAC agrees with the assessment of the DS on the physical hazards and proposes **no classification**.

9 TOXICOKINETICS (ABSORPTION, METABOLISM, DISTRIBUTION AND ELIMINATION)

Table 13: Summary table of toxicokinetic studies

Method	Results	Remarks	Reference
Dermal absorption *in vitro* in human abdominal or breast skin membranes (n=8) from 4 female donors Hexyl salicylate undiluted or as 0.1 and 20% in dipropylene glycol Diffusion cell: 9 mm automated flow-through cells Receptor fluid: physiological saline with 6% PEG 20 Exposure was terminated by washing at 8h with a 3% soap solution and the skin membranes were tape-stripped at termination of the study 24h after exposure Separate metabolism phase: 0.1% 14C-radiolabelled hexyl salicylate in dipropylene glycol applied to breast or abdomen skin membranes (n=3) from 2 female donors According to OECD Guideline 428; GLP compliant	Amount in receptor fluid: 0.15%, 0.64% and 1.00% hexyl salicylate at concentrations of 100, 20 and 0.1% resp. Separate metabolism phase: absence of hexyl salicylate in the receptor fluid but salicylic acid as major component; hexyl salicylate and salicylic acid identified in the skin extracts. => Calculation of dermal absorption taking into account the potential for metabolism to salicylic acid in viable skin: dermal absorption values of 0.8%, 7.8% and 2.7%, for hexyl salicylate concentrations of 100%, 20% and 0.1% resp.	1 (reliable without restriction) key study experimental result Test material (EC name): hexyl salicylate	Study report (2016) Cited in Lapczynski *et al.* (2007) and Belsito *et al*. (2007)

9.1 Short summary and overall relevance of the provided toxicokinetic information on the proposed classification(s)

Data specifically related to the toxicokinetics of hexyl salicylate are limited. Information was only identified for dermal absorption of this substance. Distribution, metabolism and elimination were not investigated.

Oral route

No information on toxicokinetics after oral administration is available. According to REACH guidance document 7c, although the low water solubility (2 mg/L) and Log P of 5.5 indicates that hexyl salicylate would be poorly absorbed but could be taken up by micellular solubilisation, the molecular weight of 222.2 g/mol is favourable for oral absorption of hexyl salicylate.

An oral absorption from gastrointestinal tract for 1 mg dose is estimated at 100% and for 1000 mg dose at 95% by the DK QSAR database.

Dermal route

An *in vitro* dermal absorption test with freshly isolated human excised skin was performed by the registrant according to OECD Test Guideline 428 (Table 24). Three different conditions of dermal absorption (hexyl salicylate undiluted or as 0.1 and 20% in dipropylene glycol) were tested. After 24h-exposure, small amounts of hexyl salicylate were detected in the receptor fluid (0.15%, 0.64% and 1.00% at concentrations of 100, 20 and 0.1% respectively). In a separate metabolism phase, 0.1% of 14C-radiolabelled hexyl salicylate in dipropylene glycol was applied to breast or abdomen skin membranes (n=3) from two female donors using static diffusion cells and tissue culture medium as receptor fluid. Analysis of the receptor fluid showed an absence of hexyl salicylate, but identified salicylic acid as the major component, indicating extensive metabolism of hexyl salicylate by dermal esterases. Hexyl salicylate and salicylic acid were identified in the skin extracts. The authors indicated that calculation of dermal absorption for hexyl salicylate should take into account the potential for metabolism to salicylic acid in the skin. As non-viable skin membranes were used in the first phase of the study (diffusion cells), little or no metabolism would have occurred. Thus, the dermal absorption values in this first phase might underestimate the total level of absorption. The authors concluded that that all the hexyl salicylate present in the skin was potentially metabolised and absorbed as salicylic acid. Therefore, the calculated dermal absorption values were 0.8%, 7.8% and 2.7% for hexyl salicylate concentrations of 100, 20 and 0.1% respectively. It could not be explained why the dermal absorption values were not linear with dilution.

Dermal absorption of various salicylates including hexyl salicylate was investigated by Watkinson *et al.* (1992) using a mathematic method to estimate total body absorption (assumed applied dose of 40 µg/cm^2 and assumed body surface area of 1.4 m^2). Rate constants were calculated from the relevant physico-chemical properties. The estimated total body absorption of hexyl salicylate was 27 µg over 1.4 m^2 at 12h, which is equivalent to a dermal absorption rate of 0.005%. This study was summarized in several reviews (CIR, 2018, Lapczynski *et al*., 2007, Belsito *et al*., 2007). However, it is considered unreliable as the origin of default parameters in the prediction model is unknown.

Additionally, with a water solubility of 2 mg/L for hexyl salicylate, dermal absorption is anticipated to be low to moderate according to the REACH guidance document 7c, which is in line with the *in vitro* study. The Log P of 5.5 indicates that the rate of penetration may be limited by the rate of transfer between the stratum corneum and the epidermis, but uptake into the stratum corneum will be high. The DK QSAR database estimates the dermal absorption of hexyl salicylate at 0.00358 mg/cm^2/event.

Inhalation route

No information on toxicokinetics after inhalation is available. According to REACH guidance document 7c, the low vapour pressure (7.7x10^{-5} kPa), the Log P of 5.5 and the low water solubility indicate that hexyl salicylate would be poorly absorbed by inhalation route but could be taken up by micellular solubilisation.

Conclusion

No data is available regarding oral and inhalation absorption of hexyl salicylate. Based on Log P and water solubility, hexyl salicylate is expected to be poorly absorbed by inhalation route. Regarding oral absorption, available data (log P, water solubility, DK QSAR) are contradictory. Without experimental data, no conclusion can be drawn for oral route. For dermal route, the reported absorption varied from 0.8% to 7.8%

for concentrations between 100 and 0.1% hexyl salicylate, taking into account the potential for metabolism to salicylic acid in viable skin.

Data from structurally-related salicylates indicate wide distribution *via* blood and no bioaccumulation is expected after oral and dermal exposure. Rapid metabolism by hydrolysis to liberate free salicylic acid is observed. In the case of hexyl salicylate, extensive metabolism to salicylic acid by human skin esterases was observed in an *in vitro* dermal absorption test. Metabolism would also produce the corresponding alcohol (hexanol) as initial metabolite. The QSAR Toolbox confirmed these two initial metabolites and predicted that hexyl salicylate would also be biotransformed into hexanal and hexanoic acid. Salicylates are mainly and rapidly excreted in the urine.

10 EVALUATION OF HEALTH HAZARDS

Acute toxicity

Not assessed in this report.

10.1 Skin corrosion/irritation

Not assessed in this report.

10.2 Serious eye damage/eye irritation

Not assessed in this report.

10.3 Respiratory sensitisation

Not assessed in this report.

10.4 Skin sensitisation

Table 14: Summary table of animal studies on skin sensitisation

Method, guideline, deviations if any	Species, strain, sex, no/group	Test substance,	Dose levels duration of exposure	Results	Reference
Local lymph node assay equivalent or similar to OECD Guideline 429 GLP compliant	Mouse (CBA), female, 4/group	Hexyl salicylate Purity = 98.5%	1, 2.5, 5, 10, 25% w/v (experiment 1) 0.05, 0.25, 0.5, 1, 2.5% w/v (experiment 2) Vehicle used: 1:3 ethanol:diethylphtalate Daily for 3 consecutive days	**Positive** Stimulation index (relative to vehicle control): First experiment: > 3 at all concentrations Second experiment: 0.05%: 1.87 0.25%: 3.56 0.5%: 5.60 1%: 10.83 2.5%: 10.80 EC3 = 0.18%	Unnamed (2006) Cited in SCCS Opinion on Fragrance allergens in cosmetic products (2011) Klimisch score = 1
Modified Draize test Induction: 4 intradermal injections (0.1 mL at 0.25%) First challenge: intradermal injection 14 days later (0.1 mL at 0.1%) and topical application	Inbred Hartley albino guinea pigs 4 or 6 of each sex, 10 total	Hexyl salicylate	0.25% for intradermal induction 0.1% and 5% for challenge (vehicle not	**Positive** Sensitisation reactions observed after the second challenge at 5%	Sharp (1978) Cited in Lapczynski *et al*. (2007) Klimisch score

Method, guideline, deviations if any	Species, strain, sex, no/group	Test substance,	Dose levels duration of exposure	Results	Reference
(0.1 mL at 5%) Second challenge conducted 7 days later Secondary literature Limitations: vehicle not specified			reported)		= 4
Maximisation assay Intradermal induction: 6 injections (2 x 0.1 mL injections of 1% HS in 0.01% DOBS/saline, 2 x 0.1 mL injections of 1% HS in 50% Complete Freund's Adjuvant and 2 x 0.1 mL injections of 50% Complete Freund's Adjuvant Topical induction 7 days later: 40% HS in acetone (48h occluded patch) Topical challenge 13-14 days later: 10% HS in acetone (24h occluded patch) Secondary literature Similar to OECD 406 Limitation: few number of animals, tested concentrations not justified	Dunkin/ Hartley albino guinea pigs, 10 total	Hexyl salicylate	1% in 0.01% DOBS/saline and 1% in 50% Complete Freund's Adjuvant for intradermal induction 40% in acetone for topical induction 10% in acetone for challenge	Negative	Lapczynski *et al*. (2007) Klimisch score = 3
Sensitisation evaluated as part of a photoallergy study Intradermal induction: injection of 0.1 mL of a formulation of sterile water and Freund's complete adjuvant (1:1 v/v) Topical induction: 0.3 mL of 100% HS in 3:1 DEP:ethanol applied to 25 mm Hilltop Chambers® and then to the dorsal skin of animals (occluded patch for 2h) Followed by UVR exposure using a 6.5 kW long-arc xenon water-cooled lamp with a filter used to attenuate mid-range UVB. Delivered dose: 2.25 Minimal Erythema Doses (MED) (~2.25h). Procedure repeated once daily on days 3, 5, 8, 10 and 12 of the induction phase	Male albino hairless guinea pigs (5/group)	Hexyl salicylate	100% for topical induction 50 and 100% HS in 3:1 DEP:ethanol for topical challenge	Negative	Lapczynski *et al*. (2007) Klimisch score = 3

Method, guideline, deviations if any	Species, strain, sex, no/group	Test substance,	Dose levels duration of exposure	Results	Reference
Topical challenge on day 22: 50% HS in 3:1 DEP:EtOH and 100% HS Observations 1, 4h later and 1, 2, 3 days later. Secondary literature					

Table 15: Summary table of human data on skin sensitisation

Type of data/report	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
Induction studies				
Human repeated insult patch test (HRIPT) with 103 volunteers (29 male and 74 female)	30% hexyl salicylate in 3:1DEP:EtOH	Nine induction applications, 3 per week over a 3-week period After 2 weeks rest period, single application challenge test. Reactions were scored at 24h after challenge.	0/103 positive reactions Induction phase: 3 subjects with equivocal transient reactions After challenge: 2 subjects with equivocal transient responses	RIFM (2004a) Cited in Lapczynski *et al*. (2007)
Human maximisation with 22 selected volunteers	3% hexyl salicylate probably formulated in petrolatum	Applications of 3% hexyl salicylate in petrolatum under occlusion for 5 alternate-day 48h periods after pretreatment of patch site for 24h with 5% aqueous SLS under occlusion. After 10-14 days rest period, 2% SLS was applied under occlusion for 30 min on the left side of the back prior to challenge patch of hexyl salicylate under occlusion for 48h on the right side.	Initial positive "equivocal" reactions after challenge Subjects are re-tested later. No positive evidence of sensitisation was observed.	RIFM (1975b) Cited in Lapczynski *et al*. (2007)
Diagnostic studies				
Patch test in 218 fragrance sensitive patients with contact dermatitis (selected patients)	5% hexyl salicylate in petrolatum	Various fragrance materials including hexyl salicylate	0% positive reactions	Larsen *et al*. (2002) Cited in Lapczynski *et al*. (2007) and in SCCS Opinion on Fragrance allergens in cosmetic products (2011)
Patch test in ~100 patients with dermatitis (unselected patients)	5%, 7.5%, 11.3%, 16.9%, 25.3% hexyl salicylate	Test material suspended in pet. was applied to the upper back in Finn Chambers under occlusion for 2 days. Patch test readings performed on day (D) 2, D3, D4, D5 and D7	0% positive reactions in all test concentrations 5%: 2/100 "doubtful" reactions 16.9%: 1/100 "doubtful" reactions	Bennike *et al*. (2019)

Type of data/report	Test substance,	Relevant information about the study (as applicable)	Observations	Reference
			25.3%: 1/87 "doubtful" reactions	

10.4.1 Short summary and overall relevance of the provided information on skin sensitisation

Animal data

Some studies were available to assess skin sensitisation property of hexyl salicylate, including two standard test methods, LLNA and maximisation test. Hexyl salicylate was tested diluted in various solvents (1:3 ethanol:diethylphtalate, acetone or petrolatum) and tested concentrations ranged from 0.05 to 100%.

The key study is the LLNA which is in compliance with OECD Guideline 429 (Unnamed (2006)). Hexyl salicylate is positive in this test. Dose-response could be observed and the stimulation index was higher than 3, in both experiments performed, from 0.25% to 25% (the maximum concentration tested) hexyl salicylate in 1:3 ethanol:diethylphtalate, leading to an EC_3 of 0.18%.

Hexyl salicylate was not sensitising in a maximisation test and a photoallergy study evaluating sensitisation. These two studies summarized in the above table were cited in the review from Lapczynski *et al*. (2007). However, they were both considered unreliable because few animals were tested. In the maximisation test, at least 20 test animals are indeed recommended if it is not possible to conclude that the substance is a sensitiser with fewer than 20 test animals. This may be an explanation of the negative results. In addition, in the maximisation assay, there is no justification for the tested concentrations.

In a modified Draize test, 5% hexyl salicylate induced sensitising reactions in Hartley albino guinea pigs after a second challenge. A limitation of this test was that the vehicle used was not specified.

In a genomic allergen rapid detection assay utilising an *in vitro* model of dendritic cells, hexyl salicylate was predicted to be a skin sensitiser (Forreryda *et al*. (2018), cited in the Cosmetic Ingredient Review on salicylic acid and salicylates (2019)).

Overall, **hexyl salicylate was positive at concentrations above 0.25% in the LLNA, the only animal study of good quality available, with an EC_3 = 0.18%, indicating a strong potency of sensitisation. This result is supported by a genomic allergen rapid detection assay predicting hexyl salicylate as skin sensitiser.**

Human data

Some human data are available including 2 human volunteer induction studies and 2 diagnostic studies.

No sign of sensitisation to hexyl salicylate (30% in 3:1DEP:EtOH) was reported in one HRIPT (human repeated insult patch test) performed on 103 volunteers (RIFM (2004a), cited in Lapczynski *et al*. (2007)). During the induction phase, 3 subjects showed equivocal transient reactions, which could be linked to irritation, as hexyl salicylate was repeatedly applied on the same site. Equivocal transient responses were also observed in 2 subjects after challenge but it was not mentioned if these subjects were the same as during the induction phase. These equivocal reactions after challenge should have raised concern and led to further investigation with a second reading after 48h, followed by a re-challenge 3 weeks later. Besides, when a test shows several questionable results during the induction phase, the substance application site should be changed (ANSM 2008). Additionally, benzyl salicylate was used as negative control in this study whereas this substance will be soon classified Skin Sens. 1B under the CLP regulation. This information may question the negative result of this study. Finally, the number of tested volunteers remains low (103) in comparison with the recommendations of the Scientific Committee on Consumer Safety (SCCS) (150-200 volunteers). Although the equivocal reactions after challenge may be linked to irritation, due to the tested concentration of hexyl salicylate (30%), the reported data do not allow to rule out an allergic reaction.

Considering these limitations, this HRIPT is not considered reliable.

A maximisation assay performed on 22 selected volunteers also concluded that hexyl salicylate was not sensitising (RIFM (1975b) cited in Lapczynski *et al*. (2007)). The study report indicated that positive equivocal reactions were observed after the challenge phase. Biopsies of these reactions were performed and it was followed by re-challenge, which produced no positive evidence of sensitisation. Although the test was performed on 22 volunteers instead of 25, it was overall in compliance with the method. The number of volunteers was low to be able to get statistical values. Nevertheless, the use of sodium lauryl sulphate as adjuvant in order to maximise the reaction increases the risk of sensitising reactions.

Finally, two diagnostic studies were considered negative (Larsen (2002) and Bennike (2009)).

Bennike *et al*. studied three fragrance substances, including hexyl salicylate, on unselected patients with dermatitis, as discrepancies on their sensitising properties were observed in animal and human data. These 3 substances were classified as contact allergens on the basis of animal data but not in humans (SCCS 2011). Moreover, as these substances are widely used in consumer products, exposure is commonly occurring. Thus, the study aimed at studying increasing concentrations of these substances in order to determine their optimal patch test concentrations. Five concentrations of hexyl salicylate, from 5 to 25%, were tested on approximately 100 patients with dermatitis per concentration group. Some patients showed doubtful reactions at first reading but these reactions were not confirmed at second reading. The authors concluded that no positive patch test reactions occurred with hexyl salicylate up to a concentration of 25% and that the maximum tolerated concentration for most of the patients was 12.5% hexyl salicylate. This concentration was then recommended for patch testing. Additionally, they concluded that although the possibility of contact allergy to hexyl salicylate cannot be ruled out from this study, it seems unlikely that this substance is an extreme sensitizer in humans, contrary to in animals.

The study from Larsen *et al*. was performed according to internationally accepted criteria. It included 218 selected fragrance sensitive patients with contact dermatitis. It aimed at identifying new sensitising substances to screen on patients with suspect fragrance allergy. The 218 patients were exposed to a fragrance mixture (FM) and 17 individual fragrance materials including hexyl salicylate. The FM did not contain hexyl salicylate. This mixture induced positive reactions in 76% of the subjects. The patch test following the exposure to 5% hexyl salicylate appeared negative.

Finally, no case reports were reported in the literature for patients with dermatitis after the use of a product containing hexyl salicylate.

Differentiation between sensitising and irritating reactions

Contradictory results were found in both animal and human studies. In animals, positive effects were reported in one LLNA. The results of the LLNA suggested that hexyl salicylate would be a strong sensitiser as the EC_3 is clearly below 2%. As supporting data, hexyl salicylate was predicted to be as a skin sensitiser in a genomic allergen rapid detection assay. Data from other studies (maximisation assay and photoallergy study) showed negative results. In humans, studies were all considered negative, despite some methodological deficiencies (in particular in HRIPT). Special caution has to be paid to differentiate if the positive results are linked to irritating or real sensitising effects of hexyl salicylate.

Some studies from the literature indicated that the positive result of the LLNA was considered a false-positive since hexyl salicylate up to 30% has not been sensitising in humans in one HRIPT (Roberts *et al*. 2015a & b). This argument should be discounted as the reliability of this HRIPT is questionable and negative human data cannot normally be used to negate positive results from animal studies according to the CLP regulation.

Another study explained the positive result of the LLNA by mentioning that the very low EC_3 (0.18%) might be due to irritating properties of hexyl salicylate or potential sensitising impurities (Urbisch *et al.* 2015).

From the literature, contradictory results were found regarding irritating properties of hexyl salicylate (Lapczynski *et al*. 2007, Belsito *et al*. 2007). However, it can be noted that irritation was only observed for high concentrations of hexyl salicylate: at least 25% but rather with concentrations above 50%. These concentrations are clearly above the concentrations for which skin sensitisation was observed in the LLNA.

Table 16: Summary table of animal data on skin irritation (extracted from Belsito *et al*. 2007)

Material	Method	Concentration	Species	Results	References
Hexyl salicylate	Irritation evaluated during an associated LD_{50} study	100%	10 Rabbits	Irritation observed	RIFM (1975a)
Hexyl salicylate	Primary skin irritation study (4-h occlusive patch)	10%, 15%, 25%, 50%, and 100% in DEP	4 Female New Zealand White Rabbits	10%, 15%, and 25%: no irritation 50% and 100%: irritation observed	RIFM (1986b)
Hexyl salicylate	Pre-test for Draize assay (dermal application)	5% (vehicle not specified)	4 Hartley albino guinea pigs	No irritation	Sharp (1978)
Hexyl salicylate	Irritation studied as part of a phototoxicity test	100%	6 Mice (hairless)	No irritation	RIFM (1975f)
Hexyl salicylate	Irritation studied as part of a phototoxicity test	100%	Miniature swine	No irritation	RIFM (1975f)
Hexyl salicylate	Irritation studies as part of a photoallergy test (2-h exposure with Hilltop chambers)	1%, 5%, 10%, 50%, 100% in 3:1 DEP:ethanol	Male albino hairless guinea pigs (5/group)	No irritation	RIFM (2003)
Hexyl salicylate	Preliminary irritation study	10%, 25% and 50% in acetone	4 Albino guinea pigs	10%; no irritation 25 and 50%: irritation observed	RIFM (1981e)
Hexyl salicylate	Primary skin irritation study (4-h semi-occlusive patch)	100%	3 New Zealand White Rabbits	Irritation observed	RIFM (1984) and RIFM (1985)
Hexyl salicylate	Primary skin irritation study (4-h occlusive patch)	10%, 15%, 50%, and 100% in DEP	4 Female New Zealand White Rabbits	10%, 15%, 25%, and 50%: no irritation 100%: irritation observed	RIFM (1986a)

Additionally, moderate skin irritation was reported in an OECD Guideline 404 study available in the registration dossier (Haynes, 1986). In this study, female rabbits were exposed to 50% and 100% hexyl salicylate in DEP for 4 hours under semi-occlusive conditions. At 50% hexyl salicylate, the mean erythema and oedema scores were respectively 2.0 and 1.4. The observed effects were fully reversible within 7 days. For the undiluted substance, the mean scores for erythema and oedema over the 24-72 hour period were respectively 2.0 and 2.16. In this case, it was reported that one rabbit showed remaining erythema and oedema after 7 days. Nevertheless, these effects concerned only one animal and no information was available until 14 days, which is the normal observation period recommended by OECD Guideline 404. Overall, the results of the study could not trigger a classification for skin irritation according to the CLP criteria.

Table 17: Summary table of human data on skin irritation (extracted from Belsito *et al*. 2007)

Material	Method	Concentration	Subjects	Results	References
Hexyl salicylate	Maximization pre-test (48-h occluded patch)	3% (vehicle not specified)	22 volunteers	No irritation (0/22)	RIFM (1975d)
Hexyl salicylate	Induction phrase HRIPT (24-h occluded patch, nine applications)	30% in 3:1 DEP:ethanol	103 volunteers	Slight irritation observed in 3/103	RIFM (2004a)
Hexyl salicylate	A 24-h occluded patch	0.3%, 3%, and 30% in 3:1 DEP:ethanol	56 volunteers	No irritation (0/56)	RIFM (2004b)
Hexyl salicylate	4-h occluded patch	100%	30 volunteers	No irritation (0/30)	Basketter et al. (2004)

In humans, hexyl salicylate does not seem to induce skin irritation based on the data available.

Therefore, the arguments from Urbisch *et al*. 2015, considering the result of the LLNA as false-positive due to the potential irritating properties of hexyl salicylate, cannot be considered as valid.

Regarding the other argument from these authors involving potential sensitising impurities, the purity of hexyl salicylate is > 98% and there are no impurities in amount exceeding 1% based on registration data. Besides, no impurities that would impact the classification of hexyl salicylate were identified.

Overall, there is no sufficient information to discount the effects reported in the LLNA. Thus the reported positive reactions should be considered as sensitising effects.

10.4.2 Comparison with the CLP criteria

The decision logic for classification of substance described in the CLP guidance version 5.0 (July 2017) has been followed:

"Are there data and/or information to evaluate skin sensitisation?"

Yes, there are both experimental animal studies and human data assessing skin sensitisation properties of hexyl salicylate.

a) "*Is there evidence in humans that the substance can lead to sensitisation by skin contact in a substantial number of persons, or*

No, there is no evidence in humans that the substance can lead to sensitisation by skin contact in a substantial number of persons. However, the HRIPT was considered unreliable due to methodological deficiencies.

a) Are there positive results from an appropriate animal test or in vitro/in chemico test?"

Positive results were obtained in a LLNA performed with hexyl salicylate at concentrations from 0.25%. Hexyl salicylate was predicted to be a skin sensitiser in a genomic allergen rapid detection assay.

"Are data sufficient for sub-categorisation?"

According to CLP, "*Substances shall be classified as skin sensitisers (Category 1) where data are not sufficient for sub-categorisation in accordance with the following criteria: (a) if there is evidence in humans that the substance can lead to sensitisation by skin contact in a substantial number of persons; or (b) if there are positive results from an appropriate animal test.*

***Sub-category 1A**: Substances showing a high frequency of occurrence in humans and/or a high potency in animals can be presumed to have the potential to produce significant sensitisation in humans. Severity of reaction may also be considered.*

***Sub-category 1B**: Substances showing a low to moderate frequency of occurrence in humans and/or a low to moderate potency in animals can be presumed to have the potential to produce sensitisation in humans. Severity of reaction may also be considered."*

Non-human and human data have been analysed to determine if they are sufficient for sub-categorisation.

Non-human data

Three types of animal tests can be used directly for classification purpose: LLNA, guinea pig maximisation test and Buehler assay.

Classification criteria according to CLP are the following:

Classification	Assay	Criteria
Subcategory 1A	LLNA	EC3 value ≤ 2%
Subcategory 1B	LLNA	EC3 value > 2%

With EC_3 values ≤ 2% in the LLNA, hexyl salicylate fulfils criteria for classification Skin Sens. 1A according to the CLP guidance.

Human data

Due to its low reliability, the HRIPT cannot be used for the purpose of classification. Nevertheless, the maximisation assay and the 2 diagnostic studies were negative and were considered reliable. The absence of sensitising reactions in these studies could be due to several reasons:

- The patch test for hexyl salicylate is not commercialized. Indeed, 46 fragrance substances are commercialized for patch testing by the firm Chemotechnique but hexyl salicylate is not part of the

list. Thus, hexyl salicylate was only tested for prospecting. This could explain why only 2 diagnostic studies with variable concentrations of this substance were published.

- Hexyl salicylate is not included in the list of the 26 sensitising fragrance substances in humans that require labelling. Thus, it would be difficult to determine if hexyl salicylate is responsible for a contact dermatitis following exposure to a fragrance.
- Although this substance is widely used in fragrances, the concentrations used are low. In face and body leave-on products, concentrations respectively range from 0.02 to 0.03% and from 0.08 to 0.12%. Maximal concentrations are related to rinse-off products and reach 0.52% in soaps and detergents (Cosmetic Ingredient Review on salicylic acid and salicylates (2018)). These concentrations are lower than concentration limits recommended by the International Fragrance Association (IFRA). **Therefore, the absence of sensitising reactions observed in humans could be due to primary prevention related to these concentration limits, more than the absence of sensitising properties.**

Overall conclusion :

Based on animal data, hexyl salicylate fulfills criteria for classification Skin Sens. 1A.

However, the discrepancies between animal data showing hexyl salicylate as an extreme sensitiser and negative human data raise question about a classification into sub-categories. Indeed, according to the CLP guidance, "classification into sub-categories is required when data are sufficient. When Category 1A cannot be excluded, Category 1 should be applied instead of Category 1B".

Thus, **Category 1 should be applied for hexyl salicylate**.

Deleted: Guidance on the Application of the CLP criteria

10.4.3 Conclusion on classification and labelling for skin sensitisation

Based on animal data, hexyl salicylate fulfills criteria for classification Skin Sens. 1A.

Although all human data are considered negative by the authors, one of them cannot be used for the purpose of classification due to its low reliability (HRIPT). Moreover, due to the significant discrepancies between positive animal data and negative human studies, sub-categorisation does not seem appropriate according to the CLP guidance.

Deleted: Guidance on the Application of the CLP criteria

With the positive results of the LLNA of good quality, Category 1A cannot be excluded. As data are not sufficient for sub-categorisation, **hexyl salicylate should be classified Skin Sens. 1 – H317 according to CLP regulation**.

RAC evaluation of skin sensitisation
Summary of the Dossier Submitter's proposal The skin sensitising property of hexyl salicylate was investigated in four animal studies, including two standard test methods, an local lymph node assay (LLNA) and a guinea pig maximisation test (GPMT). The LLNA was the only test of high quality, conducted according to OECD TG 429 which led to clearly positive results. Overall, hexyl salicylate was positive at concentrations above 0.25% in the LLNA, the only animal study of good quality available, with an EC3 = 0.18%, indicating a strong potency of sensitisation. There is also data available in two human volunteer induction studies, one human repeated insult patch test (HRIPT) and one Human maximisation (HMT) and two diagnostic studies (in selected and unselected patients). However, in humans, hexyl salicylate does not seem to

induce skin sensitisation based on the data available.

The DS proposed a classification as Skin Sens. 1.

Comments received during consultation

No comments were received on this hazard class during consultation.

Assessment and comparison with the classification criteria

Animal data

There are four studies available to assess skin sensitisation property of hexyl salicylate in a LLNA, a modified Draize test, a maximisation assay and in a photoallergy study. The studies are listed in the table below.

***Table**: Summary table of animal studies on skin sensitisation*

Method, guideline, deviations	Species, strain, sex, no./group	Concentrations, exposure duration	Results	Reference
LLNA equivalent or similar to OECD Guideline 429 GLP compliant	Mouse (CBA), female, 4/group	1, 2.5, 5, 10, 25% w/v (experiment 1) 0.05, 0.25, 0.5, 1, 2.5% w/v (experiment 2) Vehicle used: 1:3 ethanol:diethylphthalate Daily for 3 consecutive days	**Positive** Stimulation index (relative to vehicle control): First experiment: > 3 at all concentrations Second experiment: 0.05%: 1.87 0.25%: 3.56 0.5%: 5.60 1%: 10.83 2.5%: 10.80 EC3 = 0.18%	Unnamed (2006) Cited in Scientific Committee on Consumer Safety (SCCS) Opinion on Fragrance allergens in cosmetic products (2011)
Modified Draize test Induction: 4 intradermal injections (0.1 mL at 0.25%) First challenge: intradermal injection 14 days later (0.1 mL at 0.1%) and topical	Inbred Hartley albino guinea pigs 4 or 6 of each sex, 10 total	0.25% for intradermal induction 0.1% and 5% for challenge (vehicle not reported)	**Positive** Sensitisation reactions observed after the second challenge at 5%	Sharp (1978) Cited in Lapczynski *et al.* (2007)

application (0.1 mL at 5%) Second challenge conducted 7 days later Secondary literature Limitations: vehicle not specified				
Maximisation assay Intradermal induction: 6 injections (2 x 0.1 mL injections of 1% HS in 0.01% DOBS/saline, 2 x 0.1 mL injections of 1% HS in 50% Complete Freund's Adjuvant and 2 x 0.1 mL injections of 50% Complete Freund's Adjuvant Topical induction 7 days later: 40% HS in acetone (48h occluded patch) Topical challenge 13-14 days later: 10% HS in acetone (24h occluded patch) Similar to OECD 406 Limitation: low number of animals, tested concentrations not justified	Dunkin/ Hartley albino guinea pigs, 10 total	1% in 0.01% DOBS/saline and 1% in 50% Complete Freund's Adjuvant for intradermal induction 40% in acetone for topical induction 10% in acetone for challenge	Negative	cited in Lapczynski *et al.* (2007)
Sensitisation evaluated as part of a photoallergy study Intradermal induction: injection of 0.1 mL of a formulation of sterile water and Freund's complete adjuvant (1:1 v/v) Topical induction: 0.3 mL of 100% HS in 3:1 DEP:ethanol applied to 25 mm Hilltop Chambers® and then to the dorsal skin of animals (occluded patch for 2h) Followed by UVR exposure using a 6.5 kW long-arc xenon water-cooled lamp with a filter used to attenuate mid-range UVB. Delivered dose: 2.25 Minimal Erythema Doses	Male albino hairless guinea pigs (5/group)	100% for topical induction 50 and 100% HS in 3:1 DEP:ethanol for topical challenge	Negative	cited in Lapczynski *et al.* (2007)

(MED) (~2.25h). Procedure repeated once daily on days 3, 5, 8, 10 and 12 of the induction phase Topical challenge on day 22: 50% HS in 3:1 DEP:EtOH and 100% HS Observations 1, 4h later and 1, 2, 3 days later.				

All four studies used hexyl salicylate as testing substance, whereas only in the LLNA the purity was stated to be 98.5%. Hexyl salicylate was tested diluted in various solvents (1:3 ethanol:diethylphthalate, acetone or petrolatum) and the concentrations tested ranged from 0.05 to 100%. The LLNA is considered the key study since it is in compliance with OECD TG 429. In this test, hexyl salicylate gave a positive result with a clear dose response from the lowest concentration tested (0.05%). The test was performed twice and the stimulation index was >3 in both experiments performed from 0.25% to 25% hexyl salicylate in 1:3 ethanol:diethylphthalate, leading to an EC3 of 0.18%.

In a maximisation test and a photoallergy study evaluating sensitisation hexyl salicylate was negative. However, although the maximisation assay was performed similar to OECD 406 the number of animals tested was too low, with 10 animals used instead of at least 20 animals recommended. In addition, there is no justification for the concentrations used.

Limitations of the low number of animals also apply to the photoallergy study, where 5 animals per group were used.

In a modified Draize test, 5% hexyl salicylate induced sensitising reactions in Hartley albino guinea pigs after a second challenge. The lack of specification of the vehicle used was a limitation in this test.

In a genomic allergen rapid detection (GARD) assay utilising an *in vitro* model of dendritic cells, hexyl salicylate was predicted to be a skin sensitiser (Forreryda *et al.* (2018), cited in the Cosmetic Ingredient Review on salicylic acid and salicylates (2019)).

Human data

Two human volunteer induction studies and two diagnostic studies where available as listed in the table below.

Table*: Summary table of human data on skin sensitisation*

Type of data/report	**Test substance**	**Relevant information about the study (as applicable)**	**Observations**	**Reference**
Induction studies				
Human repeated insult patch test (HRIPT) with 103	30% hexyl salicylate in 3:1DEP:EtOH	Nine induction applications, 3 per week over a 3-week	0/103 positive reactions Induction	RIFM (2004a) Cited in Lapczynski *et al.*

volunteers (29 male and 74 female)		period After 2 weeks rest period, single application challenge test. Reactions were scored at 24h after challenge.	phase: 3 subjects with equivocal transient reactions After challenge: 2 subjects with equivocal transient responses	(2007)
Human maximization test (HMT) with 22 selected volunteers	3% hexyl salicylate probably formulated in petrolatum	Applications of 3% hexyl salicylate in petrolatum under occlusion for 5 alternate-day 48h periods after pretreatment of patch site for 24h with 5% aqueous SLS under occlusion. After 10-14 days rest period, 2% SLS was applied under occlusion for 30 min on the left side of the back prior to challenge patch of hexyl salicylate under occlusion for 48h on the right side.	Initial positive "equivocal" reactions after challenge Subjects are re-tested later. No positive evidence of sensitisation was observed.	RIFM (1975b) Cited in Lapczynski *et al.* (2007)
Diagnostic studies				
Patch test in 218 fragrance sensitive patients with contact dermatitis (selected patients)	5% hexyl salicylate in petrolatum	Various fragrance materials including hexyl salicylate	0% positive reactions	Larsen *et al.* (2002) Cited in Lapczynski *et al.* (2007) and in SCCS Opinion on Fragrance allergens in cosmetic products (2011)
Patch test in ~100 patients with dermatitis (unselected patients)	5%, 7.5%, 11.3%, 16.9%, 25.3% hexyl salicylate	Test material suspended in pet. was applied to the upper back in Finn Chambers under occlusion for 2 days. Patch test readings performed on day (D) 2, D3, D4, D5 and D7	0% positive reactions in all test concentrations 5%: 2/100 "doubtful" reactions 16.9%: 1/100 "doubtful" reactions 25.3%: 1/87 "doubtful" reactions	Bennike *et al.* (2019)

In a HRIPT, no signs of sensitisation of hexyl salicylate (30%) were reported on 103 volunteers. Three subjects showed equivocal transient reactions during the induction phase, which might be linked to irritation, as the test substance was repeatedly applied to the same site. Two further subjects had equivocal transient responses after challenge. However, it is not clear if they were the same as during the induction phase. Due to these reactions, a second reading was performed after 48h, followed by a re-challenge 3 weeks later. Benzyl salicylate was used as negative control in this study whereas this substance was recently proposed by RAC for Skin Sens. 1B under the CLP regulation. This information may question the negative result of this study. In addition, the number of tested volunteers was low (103) in comparison with the recommendations of the Scientific Committee on Consumer Safety (SCCS) (150-200 volunteers). Although the equivocal reactions after challenge may be linked to irritation, the reported data do not allow to rule out an allergic reaction. Considering these limitations, this HRIPT is not considered reliable.

A maximisation assay performed on 22 selected volunteers gave negative results with positive equivocal reactions being observed after the challenge phase but not after a re-challenge. The test was performed on 22 volunteers instead of 25, but it was overall in compliance with the method. However, the use of sodium lauryl sulphate as adjuvant in order to maximise the reaction increases the risk of sensitising reactions.

In a diagnostic study Larsen *et al.* included 218 selected fragrance sensitive patients with contact dermatitis. It aimed at identifying new sensitising substances to screen on patients with suspect fragrance allergy. The 218 patients were exposed to a fragrance mixture (FM) and several individual fragrance materials including hexyl salicylate. The FM did not contain hexyl salicylate. This mixture induced positive reactions in 76% of the subjects. The patch test following the exposure to 5% hexyl salicylate appeared negative.

Bennike *et al.* investigated hexyl salicylate on unselected patients with dermatitis. As the substance is used in consumer products, exposure is commonly occurring. The substance was tested in concentrations from 5 to 25% on approximately 100 patients with dermatitis per concentration group. Some patients showed doubtful reactions at first reading but these reactions were not confirmed at second reading. According to the authors, no positive patch test reaction occurred up to a concentration of 25% and the maximum tolerated concentration for most of the patients was 12.5%.

There are no case reports in the literature for patients with dermatitis after the use of a product containing hexyl salicylate.

Skin sensitising vs skin irritating reactions

Contradictory results were found in both animal and human studies. In animals, positive effects were reported in one LLNA. The results of the LLNA suggested that hexyl salicylate would be a strong sensitiser as the EC3 is clearly below 2%. In addition, hexyl salicylate was predicted to be a skin sensitiser in a GARD assay but data from other studies (maximisation assay and photoallergy study) showed negative results. In humans, studies were all considered negative, despite some methodological deficiencies (in particular in HRIPT). Special caution has to be paid to differentiate if the positive results are linked to irritating or sensitising effects of hexyl salicylate.

Some studies published in the open literature indicated that the positive result of the LLNA was considered false positive because hexyl salicylate was non-sensitising up to 30 % in a human HRIPT (Roberts *et al.* 2015a & b). This argument should be disregarded as the

reliability of this HRIPT is questionable and negative human data cannot normally be used to negate positive results from animal studies according to the CLP Regulation. Another study explained the positive result of the LLNA by mentioning that the very low EC3 (0.18%) might be due to irritating properties of hexyl salicylate or potential sensitising impurities (Urbisch *et al.* 2015).

Contradictory results were found in literature regarding irritating properties of hexyl salicylate (Lapczynski *et al.* 2007, Belsito *et al.* 2007). However, it can be noted that irritation was only observed for high concentrations of hexyl salicylate: at least 25% but rather with concentrations above 50%. These concentrations are clearly above the concentrations for which skin sensitisation was observed in the LLNA.

Moderate skin irritation was also reported in an OECD Guideline 404 study available in the registration dossier (Haynes, 1986). In this study, female rabbits were exposed to 50% and 100% hexyl salicylate in DEP for 4 hours under semi-occlusive conditions. At 50% hexyl salicylate, the mean erythema and oedema scores were respectively 2.0 and 1.4. The observed effects were fully reversible within 7 days. For the undiluted substance, the mean scores for erythema and oedema over the 24-72 hour period were respectively 2.0 and 2.16. In this case, it was reported that one rabbit showed remaining erythema and oedema after 7 days. Nevertheless, these effects concerned only one animal and no information was available until 14 days, which is the normal observation period recommended by OECD Guideline 404. Overall, the results of the study could not trigger a classification for skin irritation according to the CLP criteria.

Regarding the argument of potential sensitising impurities, the purity of hexyl salicylate in the LLNA is > 98% and there are no impurities in amount exceeding 1% based on registration data. Besides, no impurities that would impact the classification of hexyl salicylate were identified.

There is no indication of irritating effects of hexyl salicylate in humans.

Overall, there is no sufficient information to discount the effects reported in the LLNA. Thus, the reported positive reactions should be considered as sensitising effects.

Conclusion

With EC3 values $\leqslant$ 2% in the LLNA, hexyl salicylate fulfils criteria for classification Skin Sens. 1A according to the CLP guidance. Regarding human data, the HRIPT cannot be used for the purpose of classification due to its low reliability. Nevertheless, the maximisation assay and both diagnostic studies were negative and were considered reliable.

There are several possible reasons for the absence of sensitising reactions in these studies:

- The patch test for hexyl salicylate is not marketed. In fact, 46 fragrances are marketed by Chemotechnique for patch testing, but hexyl salicylate is not part of the list. Hexyl salicylate was therefore only tested for prospecting purposes. This could explain why only 2 diagnostic studies with different concentrations of this substance have been published.
- Hexyl salicylate is not included in the list of 26 sensitising fragrances for humans that require labelling. Therefore, it would be difficult to determine whether hexyl salicylate is responsible for contact dermatitis following exposure to a fragrance.

- Although this substance is widely used in perfumes, the concentrations used are low. In leave-on products for face and body, the concentrations are between 0.02 and 0.03 % and between 0.08 and 0.12 %, respectively. The highest concentrations are used in rinse-off products, reaching 0.52 % in soaps and cleansers (Cosmetic Ingredient Review on salicylic acid and salicylates (2018)). These concentrations are below the concentration limits recommended by the International Fragrance Association (IFRA).

Therefore, the absence of sensitising reactions observed in humans could be due to primary prevention related to these concentration limits, more than the absence of sensitising properties.

Due to the significant discrepancies between positive animal data and negative human studies, sub-categorisation does not seem appropriate according to the CLP guidance.

With the positive results of the LLNA of good quality, Category 1A would be justified. However, since data are not sufficient for sub-categorisation, RAC agrees to the DS that hexyl salicylate should be classified Skin Sens. 1 – H317.

Deleted: Guidance on the Application of the CLP criteria

10.5 Germ cell mutagenicity

Not assessed in this report.

10.6 Carcinogenicity

Not assessed in this report.

10.7 Reproductive toxicity

10.7.1 Adverse effects on sexual function and fertility

No fertility studies are available on hexyl salicylate. Therefore, assessment of the potential of hexyl salicylate to impair fertility has been based on read-across data from animal studies on methyl salicylate (MeS) (see Annex II for rationale). The read-across approach is considered adequate since both methyl salicylate and hexyl salicylate metabolize to form salicylic acid (SA). No fertility studies are available with salicylic acid. In the RAC opinion dated on 2016 for salicylic acid, a read-across to methyl salicylate was agreed.

Table 18: Summary table of animal studies on adverse effects on sexual function and fertility

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Study of fertility and early embryonic development to implantation Crj:CD(SD)IGS rats male/female Subcutaneous	Methyl salicylate (purity: 100.1%) 0, 30, 100, 300 mg/kg/day in corn oil From 2 weeks prior to mating until sacrifice (total of 52 days) for males and until gestation day 6 for females (total of 30 days). Sacrifice of	NOAEL for general toxicity: 100 mg/kg/day based on one mortality in males, decreased body weight gain and food consumption at 300 mg/kg bw/day. NOAEL for fertility: 300	FDA (2006a) Klimisch score : 1 Key study **(See Annex I**

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
administration GLP and ICH guidelines	females on GD13.	mg/kg/day (no effect). Increased plasmatic salicylic acid concentration dependent on the dose ratio but scarcely affected by repeated dosing. No clear sexual difference.	**for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 4 (offspring assessment) of the NTP continuous breeding protocol Limited examination NTP protocol, GLP	Methyl salicylate (purity ≥ 99%) 0, 25, 50 and 100 mg/kg/day. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). A second generation was then produced only for the highest dose group (task 4): the mothers were dosed through weaning and F1 mice were dosed until mated at about 74 days of age.	NOAEL (reproductive effects): 100 mg/kg bw/day – no adverse effect	NTP (1984a) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Lamb *et al*., (1997) Klimisch score : 2 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
One generation study + crossover mating study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 3 (crossover mating) of the NTP continuous breeding protocol Limited examination NTP protocol, GLP	Methyl salicylate (purity ≥ 99%) 100, 250 and 500 mg/kg/day. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). Task 3: high-dose animals of each sex were mated to control mice of the opposite sex.	500 mg/kg bw/day – no effect on fertility index Task 3: due to fertility problem in the control groups (26% in the first task 3 and 41% in the second task 3) and lack of significant results in the litter analysis, an affected sex cannot be determined.	NTP (1984b) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Klimisch score : 2 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Three-generation study	Methyl salicylate	NOAEL (fertility): 250 mg/kg bw/day (male/female) based on	Collins TFX *et al.* (1971)

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Rat (Osborne-Mendel); male/female (20/sex/dose) Oral: feed (no vehicle) A supplementary study was performed with adding calcium carbonate to MeS diet with the same examination. Examination very limited Several deficiencies from OECD 416, not GLP	0, 500, 1500, 3000 and 5000 ppm (equivalent to 25, 75, 150, 250 mg/kg bw as MeS) (nominal in diet) Exposure: 100 days before the first mating and then throughout the experiment (until weaning of the 3rd generation).	no statistically significant effect reported. The addition of calcium carbonate did not markedly differ from those obtained after administration of MeS alone.	Gross MA, Fitzhugh OG (1977) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Rat (Wistar) male/female 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	Methyl salicylate 0.25% and 0.5% (2500 ppm and 5000 ppm equivalent to 125 and 250 mg/kg bw MeS/day) (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (weaning of the F2b litters).	No adequate NOAEL can be set based on the low quality of the reported results. Decreased litter size at all doses. Higher number of unsuccessful matings for the first generation and decreased reproduction index for both generations at the highest dose. Higher number of death between birth and day 5 at 250 mg/kg bw/day.	Anonymous (1978a) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Mouse male/female (no data on strain); 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	Methyl salicylate 0.25% and 0.5% (2500 ppm and 5000 ppm, equivalent to 375 and 750 mg/kg bw MeS/day) (nominal in diet) Exposure: 30 days before the first mating and then throught the experiment (weaning of the pups).	No adequate NOAEL can be set based on the low quality of the reported results. Litter size slightly smaller in test groups only in the first generation.	Anonymous (1978b) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
One-generation study	Methyl salicylate	NOAEL (F1): 300 mg/kg	FDA (1966)

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
Rat (Sprague-Dawley); male/female; 24-27 animals/dose Oral: feed (no vehicle) Guideline and GLP not stated – secondary litterature	4000 ppm and 6000 ppm equivalent to 200 and 300 mg/kg bw/day (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (until weaning of offspring on day 20-21)	bw/day (male/female) based on no effect No abnormalities. Neonate survival at weaning was greater in the test group than in control.	CIR (2003) Klimisch score : 4 Disregarded study **(See Annex II for justification of read-across)**

10.7.2 Short summary and overall relevance of the provided information on adverse effects on sexual function and fertility

Animal data

According to the CLH report on methyl salicylate and the RAC opinion dated on September 2019 for this substance, the seven studies above showed no statistically significant effect on fertility and mating in rats at doses up to 250 mg/kg bw/day by oral route and 300 mg/kg bw/day by subcutaneous application and in mice at doses up to 750 mg/kg bw/day (highest doses tested). **Even if most of the fertility studies on methyl salicylate showed a number of deficiencies compared to OECD guidelines in term of parameters studied, none reported any significant and/or consistent effect on fertility. Therefore, based on a read-across with methyl salicylate, it can be concluded that hexyl salicylate is not likely to have any significant adverse effect on fertility.**

Human data

No human data has been found with hexyl salicylate.

10.7.3 Comparison with the CLP criteria

According to the CLH report on methyl salicylate and the RAC opinion dated on September 2019 for this substance, e**ven if most of the fertility studies on methyl salicylate showed a number of deficiencies compared to OECD guidelines in term of parameters studied, none reported any significant and/or consistent effect on fertility. The RAC agreed with the proposal by FR that no classification was justified for methyl salicylate for adverse effects on sexual function and fertility.**

Therefore, through a read-across with data on methyl salicylate, no classification is justified for hexyl salicylate for adverse effects on sexual function and fertility.

10.7.4 Adverse effects on development

No developmental studies are available on hexyl salicylate. Therefore, assessment of the potential of hexyl salicylate to impair development has been based on read-across data from animal studies on salicylic acid, sodium salicylate and methyl salicylate (see Annex II for rationale). The read-across approach is considered adequate since sodium salicylate, methyl salicylate and hexyl salicylate metabolize to form salicylic acid.

Table 19: Summary table of animal studies on adverse effects on development

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Data on salicylic acid			
Prenatal developmental assay (G8-14) Rat (Wistar) (female) oral: in the diet equivalent or similar to OECD Guideline 414	Salicylic acid 0.06, 0.1, 0.2, 0.4% (corresponding to 50.7 +/- 0.6, 77.4 +/- 1.0, 165 +/- 2.1, 205.9 +/- 18.9 mg/kg bw/d Exposure: day 8 to 14 (daily)	NOAEL (maternal toxicity): 165 mg/kg bw/day NOAEL (developmental toxicity): 77.4 mg/kg bw/day	Tanaka S *et al.* (1973a) Klimisch score = 2 **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Prenatal developmental assay (G8-14) Rat (Wistar) (female) oral: gavage equivalent or similar to OECD Guideline 414	Salicylic acid 75, 150, 300 mg/kg bw/d in CMC (carboxymethyl cellulose) Exposure: day 8 to 14 (daily)	NOAEL (maternal toxicity): 150 mg/kg bw/day NOAEL (developmental toxicity): 75 mg/kg bw/day	Tanaka S *et al.* (1973b) Klimisch score = 2 **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Rat (Sprague-Dawley) (17 female) subcutaneous no guideline followed Limitation: not GLP compliant	Salicylic acid 380 mg/kg (nominal conc.) Vehicle: water Exposure: 2 salicylic acid administrations at 2 hr interval, on day 9, followed by mineral isotopes administration on day 9 or 16 of pregnancy Urinary excretion and fetal uptake of the mineral isotopes were measured and the fetuses (on day 20 of gestation) were removed and inspected noting death, resorption, as well as external congenital malformations.	No NOAEL identified Marked maternal body weight loss, loss of appetite, complete relaxation, weakness, drowsiness, muscular limpness, inactivity, accelerated respiration rate, and occasionally elevated water intake and urinary excretion High incidence of fetal malformations and resorption, abnormally small fetuses	Koshakji and Schulert (1973) Klimisch score = 3 **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Data on sodium salicylate			
Prenatal developmental assay (G6-15) Rat (Sprague-Dawley) (17-19 female/dose)	Sodium salicylate 30, 90 or 180 mg/kg (nominal conc.) Vehicle: water Exposure: day 6 to 15 (daily)	NOAEL (embryotoxicity/ fetotoxicity): 90 mg/kg bw/day NOAEL (teratogenicity): 30 mg/kg bw/day	Fritz and Giese (1990) Klimisch score = 2 **(See Annex I**

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
oral: gavage equivalent or similar to OECD Guideline 414			**for more details on the results)** **(See Annex II for justification of read-across)**
Rabbit (New Zealand White) (4 female) oral: gavage Limitation: few number of animals, only one concentration tested	Sodium salicylate 100 mg/kg (actual ingested) Vehicle: water Exposure: day 4 to 7 (daily)	No effect on the number of implantations or on foetal development	Fabro S *et al.* (1984) Klimisch score = 3 **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Data on methyl salicylate			
Prenatal developmental assay (GD6-18) Rabbit New Zealand White (18-20 females/group) Subcutaneous administration Study performed according to ICH guidelines and GLP	Methyl salicylate (purity: 100.1%) 0, 30, 100, 300 mg/kg bw/day in corn oil Exposure: day 6 to 18 (daily)	NOAEL (development): 300 mg/kg/day based on no effect. NOAEL (maternal): 100 mg/kg/day based on abortion in one dam and on decreased body weight gain at 300 mg/kg/day. Increase of the plasma salicylic acid concentration nearly dependent of increases in the dose ratio and scarcely affected by repeated dosing.	FDA (2006b) Klimisch score : 1 Key study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Prenatal developmental assay (GD6-17) Rat Crj:CD(SD)IGS (20 females/group) Subcutaneous administration Study performed according to ICH guidelines and GLP	Methyl salicylate (purity: 100.1%) 0, 50, 100, 200 mg/kg bw/day in corn oil Exposure: day 6 to 17 (daily)	NOAEL (development): 100 mg/kg bw/day based on decreased body weight, external and skeletal anomalies at 200 mg/kg bw/day. NOAEL (maternal): 100 mg/kg bw/day based on depression of the body weight gain and decrease in food consumption at 200 mg/kg bw/day.	FDA (2006c) Klimisch score : 1 Key study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Study for effects on pre and postnatal development including maternal function	Methyl salicylate (purity: 100.1%) 0, 20, 60, 200 mg/kg/day in corn oil Exposure: from gestation day 6 to	NOAEL maternal: 60 mg/kg/d based on decreased body weight, food consumption and mortality at 200 mg/kg bw/day.	FDA (2006d) Klimisch score : 1

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Crj:CD(SD)IGS pregnant female rats (20/group) Subcutaneous administration. Groups of offspring sacrificed on lactation day 22 for organ weight and skeletal examination. Remaining males and females were mated to assess reproductive performance. Females sacrificed on gestation day 13. GLP and ICH guidelines	lactation day 21	NOAEL development < 60 mg/kg/day based on skeletal variations at 60 mg/kg bw/day. Decreased birth index, delayed balanopreputial separation, delayed incisor eruption and skeletal anomalies and variations at 200 mg/kg/day.	Key study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 4 (offspring assessment) of the NTP continuous breeding protocol NTP protocol, GLP	Methyl salicylate (purity ≥ 99%) 0, 25, 50 and 100 mg/kg/day. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). A second generation was then produced only for the highest dose group (task 4): the mothers were dosed through weaning and F1 mice were dosed until mated at about 74 days of age.	NOAEL (reproductive effects): 100 mg/kg bw/day – no adverse effect NOAEL (developmental effects): 100 mg/kg bw/day – no adverse effect	NTP (1984a) Chapin & Sloane (1997) Morrissey *et al*., (1989) Lamb *et al*., (1997) Klimisch score : 2 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
One generation study + crossover mating study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 3 (crossover mating) of	Methyl salicylate (purity ≥ 99%) 100, 250 and 500 mg/kg/day. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). Task 3: high-dose animals of each sex were mated to control mice of the opposite sex.	500 mg/kg bw/day – no effect on fertility index NOAEL (developmental effect): 100 mg/kg bw/day based on a reduction in pup weight from 250 mg/kg bw/day. At 500 mg/kg bw/day, a significant decrease in the mean number of litter and in the average of pups per litter, the proportion of pups born alive was observed. Task 3: due to fertility problem in the control groups (26% in the	NTP (1984b) Chapin & Sloane (1997) Morrissey *et al*., (1989) Klimisch score : 2 Supporting study **(See Annex I for more details on the results)**

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
the NTP continuous breeding protocol NTP protocol, GLP		first task 3 and 41% in the second task 3) and lack of significant results in the litter analysis, an affected sex cannot be determined.	**(See Annex II for justification of read-across)**
Three-generation study Rat (Osborne-Mendel); male/female (20/sex/dose) Oral: feed (no vehicle) A supplementary study was performed with adding calcium carbonate to MeS diet with the same examination. Examination very limited Several deficiencies from OECD 416, not GLP	Methyl salicylate 0, 500, 1500, 3000 and 5000 ppm (equivalent to 25, 75, 150, 250 mg/kg bw as MeS) (nominal in diet) Exposure: 100 days before the first mating and then throughout the experiment (until weaning of the 3rd generation).	NOAEL (fertility): 250 mg/kg bw/day (male/female) based on no statistically significant effect reported. NOAEL (development): 75 mg/kg bw/day based on statistically significant decrease of litter size, viability (D0), survival (D4), weaning data in the second generation and decreased pup body weight at 150 mg/kg bw/day. The addition of calcium carbonate did not markedly differ from those obtained after administration of MeS alone.	Collins TFX *et al.* (1971) Gross MA, Fitzhugh OG (1977) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Rat (Wistar) male/female 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	Methyl salicylate 0.25% and 0.5% (2500 ppm and 5000 ppm equivalent to 125 and 250 mg/kg bw MeS/day) (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (weaning of the F2b litters).	No adequate NOAEL can be set based on the low quality of the reported results. Decreased litter size at all doses. Higher number of unsuccessful matings for the first generation and decreased reproduction index for both generations at the highest dose. Higher number of death between birth and day 5 day at 250 mg/kg bw/day.	Anonymous (1978a) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**
Two-generation study Mouse male/female (no data on strain); 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	Methyl salicylate 0.25% and 0.5% (2500 ppm and 5000 ppm, equivalent to 375 and 750 mg/kg bw MeS/day) (nominal in diet) Exposure: 30 days before the first mating and then through the experiment (weaning of the pups).	No adequate NOAEL can be set based on the low quality of the reported results. Litter size slightly smaller in test groups only in the first generation.	Anonymous (1978b) Klimisch score : 3 Supporting study **(See Annex I for more details on the results)** **(See Annex II for justification of read-across)**

Method, guideline, deviations if any, species, strain, sex, no/group	Test substance, dose levels duration of exposure	Results	Reference
One-generation study Rat (Sprague-Dawley); male/female; 24-27 animals/dose Oral: feed (no vehicle) Guideline and GLP not stated – secondary literature	Methyl salicylate 4000 ppm and 6000 ppm equivalent to 200 and 300 mg/kg bw/day (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (until weaning of offspring on day 20-21)	NOAEL (F1): 300 mg/kg bw/day (male/female) based on no effect. No abnormalities. Neonate survival at weaning was greater in the test group than in control.	FDA (1966) CIR (2003) Klimisch score : 4 Disregarded study **(See Annex II for justification of read-across)**

10.7.5 Short summary and overall relevance of the provided information on adverse effects on development

Animal data

According to the RAC Opinion dated on March 2016 for salicylic acid and the studies listed in the above table on this substance and sodium salicylate, there is robust evidence of developmental effects in rats following exposure to salicylic acid. Salicylic acid has embryo-/foetotoxic effect in rats with dose-dependent growth delays, foetal death and malformations. Early developmental effects were clearly seen in the absence of maternal effects.

According to the CLH report on methyl salicylate and the RAC opinion dated on September 2019 for this substance, there is clear evidence of developmental effects in two well-conducted studies in rats (FDA, 2006 c, d). Following subcutaneaous exposure to 200 mg/kg bw/day of methyl salicylate, several developmental effects were observed. FDA 2006d reported lethality, growth retardation, external malformation, delay in post-natal differentiation indices, skeletal anomalies, skeletal variations and delay of ossification at this concentration. FDA 2006c observed significant lower foetal body weight, external malformations, visceral anomalies and skeletal variations. Although maternal toxicity also occurred at 200 mg/kg bw/day in these two studies, the observed developmental effects were not considered to be secondary to this maternal toxicity. Additionally, developmental effects were reported in fertility studies in both mice and rats (Collins *et al*. 1971, Anonymous 1978a, 1978b, NTP 1984b).

Therefore, based on a read-across with salicylic acid and methyl salicylate, it can be concluded that hexyl salicylate is likely to induce similar developmental effects in animals.

Human data

No human data has been found with hexyl salicylate.

10.7.6 Comparison with the CLP criteria

Based on the developmental effects observed in animal studies with salicylic acid, sodium salicylate and methyl salicylate, hexyl salicylate is likely to induce adverse effects on development. Specifically based on the data about methyl salicylate, it is assumed that the developmental effects caused by hexyl salicylate would be considered not to be secondary to maternal toxicity if it may occur at similar concentrations. Thus, this information would justify classification in Category 1B.

Nevertheless, salicylic acid has been classified by RAC in Category 2 for developmental toxicity in March 2016. In a weight of evidence approach, the concluding choice of Category 2 (instead of 1B) was mainly based on the lack of robust evidence of birth defects in humans, in particular with another salicylate compound, aspirin (acetyl salicylic acid), despite clear teratogenicity in rats. Similar approach and conclusion were reached for the classification as Repr. 2 for methyl salicylate in the RAC (2019) opinion. The same concluding choice of Category 2 is considered relevant for hexyl salicylate.

"Neither ASA nor SA are proven human developmental toxicants. There is a lack of evidence to support an increased risk of birth defects following exposure to ASA. Also, the evidence for other developmental effects has uncertainties. Taking that into account, classification in Category 1A is not justified.

In the study of Wilson et al. (1977), when general embryotoxicity of rats and monkeys to ASA was compared at equivalent dosages, some differences were detected. According to the study author this difference in effects seen can be attributable to the differences in embryonic exposure; since the free (unbound) SA is responsible for the teratogenic potential and the binding capacity differs between species, the rat embryo is exposed to higher levels and for a longer duration than the monkey embryo.

In rats plasma concentrations of salicylate 20 minutes after oral administration of methyl-or acetylsalicylate at a dose of 500 mg/kg bw were 217 ± 16.1 mg/L (MeS) and 209 ± 18.6 (ASA) and 60 minutes after dosing salicylate concentrations of 278 ± 16.7 mg/L (MeS) and 274 ± 23.5(ASA) mg/L were measured (Davison et al., 1961) indicating a similar toxicokinetic behaviour of both esters in rats.

In humans, no malformations could be detected; based on the assumption of a similar teratogenic potency in all species, a hypothetical human threshold for malformations around of 200 mg/L of total salicylate in maternal serum was calculated.

RAC is of the view that, with MeS, the situation is similar to SA and it is a matter of consistency to classify the methylester of SA accordingly."

Therefore, based on the weight of the evidence, hexyl salicylate should be classified as Repr. 2; H361d (Suspected of damaging the unborn child).

10.7.7 Conclusion on classification and labelling for reproductive toxicity

Based on a read-across with salicylic acid and methyl salicylate, the same approach was undertaken for hexyl salicylate.

Therefore, considering the RAC opinions for these substances as Repr. 2 for development, hexyl salicylate should also be classified as Repr. 2 – H361d.

No classification is proposed for toxicity on fertility.

RAC evaluation of reproductive toxicity

Summary of the Dossier Submitter's initial proposal

There are no fertility or developmental studies available for hexyl salicylate. Therefore, the assessment of reproductive toxicity has been based on read-across data from animal studies on MeS for fertility as well as SA, NaS and MeS for developmental toxicity (see Annex II of the CLH dossier for rationale). According to the DS, the read-across approach is considered adequate since NaS, MeS and hexyl salicylate metabolise to form SA.

They summarised the following studies for effects on fertility:

Method, guideline, deviations, species, strain, sex, no./group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Study of fertility and early embryonic development to implantation Crj:CD(SD)IGS rats male/female Subcutaneous administration GLP and ICH guidelines	MeS (purity: 100.1%) 0, 30, 100, 300 mg/kg bw/d in corn oil From 2 weeks prior to mating until sacrifice (total of 52 days) for males and until gestation day 6 for females (total of 30 days). Sacrifice of females on GD13.	NOAEL for general toxicity: 100 mg/kg bw/d based on one mortality in males, decreased body weight gain and food consumption at 300 mg/kg bw/d. NOAEL for fertility: 300 mg/kg bw/d (no effect). Increased plasmatic SA concentration dependent on the dose ratio but scarcely affected by repeated dosing. No clear sexual difference.	FDA (2006a) Klimisch score: 1 Key study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 4 (offspring assessment) of the NTP continuous breeding protocol Limited examination NTP protocol, GLP	MeS (purity ≥ 99%) 0, 25, 50 and 100 mg/kg bw/d (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). A second generation was then produced only for the highest dose group (task 4): the mothers were dosed through weaning and F1 mice were dosed until mated at about 74 days of age.	NOAEL (reproductive effects): 100 mg/kg bw/d – no adverse effect	NTP (1984a) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Lamb *et al.*, (1997) Klimisch score: 2 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
One generation study + crossover mating study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group.	MeS (purity ≥ 99%) 100, 250 and 500 mg/kg bw/d (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21	500 mg/kg bw/d – no effect on fertility index Task 3: due to fertility problem in the control groups (26% in the first task 3 and 41% in the second task 3) and lack of significant results in the litter analysis, an affected	NTP (1984b) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Klimisch score: 2 Supporting study

Oral: gavage in corn oil Task 2 (continuous breeding phase) & 3 (crossover mating) of the NTP continuous breeding protocol Limited examination NTP protocol, GLP	days during which final litters were delivered (task 2). Task 3: high-dose animals of each sex were mated to control mice of the opposite sex.	sex cannot be determined.	(See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Three-generation study Rat (Osborne-Mendel); male/female (20/sex/dose) Oral: feed (no vehicle) A supplementary study was performed with adding calcium carbonate to MeS diet with the same examination. Examination very limited Several deficiencies from OECD 416, not GLP	MeS 0, 500, 1500, 3000 and 5000 ppm (equivalent to 25, 75, 150, 250 mg/kg bw/d as MeS) (nominal in diet) Exposure: 100 days before the first mating and then throughout the experiment (until weaning of the 3rd generation).	NOAEL (fertility): 250 mg/kg bw/d (male/female) based on no statistically significant effect reported. The results after addition of calcium carbonate did not markedly differ from those obtained after administration of MeS alone.	Collins TFX *et al.* (1971) Gross MA, Fitzhugh OG (1977) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Rat (Wistar) male/female 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	MeS 0.25% and 0.5% (2500 ppm and 5000 ppm equivalent to 125 and 250 mg/kg bw/d MeS/day) (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (weaning of the F2b litters).	No adequate NOAEL can be set based on the low quality of the reported results. Decreased litter size at all doses. Higher number of unsuccessful matings for the first generation and decreased reproduction index for both generations at the highest dose. Higher number of death between birth and day 5 at 250 mg/kg bw/d.	Anonymous (1978a) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Mouse male/female (no data on strain); 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies	MeS 0.25% and 0.5% (2500 ppm and 5000 ppm, equivalent to 375 and 750 mg/kg bw/d) (nominal in diet) Exposure: 30 days before the first mating and then throughout the experiment (weaning of	No adequate NOAEL can be set based on the low quality of the reported results. Litter size slightly smaller in test groups only in the first generation.	Anonymous (1978b) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the

from OECD 416, not GLP	the pups).		BD for justification of read-across)
One-generation study Rat (Sprague-Dawley); male/female; 24-27 animals/dose Oral: feed (no vehicle) Guideline and GLP not stated – secondary literature	MeS 4000 ppm and 6000 ppm equivalent to 200 and 300 mg/kg bw/d (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (until weaning of offspring on day 20-21)	NOAEL (F1): 300 mg/kg bw/d (male/female) based on no effect No abnormalities. Neonate survival at weaning was higher in the test group than in control.	FDA (1966) CIR (2003) Klimisch score: 4 Disregarded study (See Annex II of the BD for justification of read-across)

For developmental toxicity, the DS summarised the following studies:

Method, guideline, deviations if any, species, strain, sex, no/group	**Test substance, dose levels duration of exposure**	**Results**	**Reference**
Data on salicylic acid			
Prenatal developmental assay (GD8-14) Rat (Wistar) (female) oral: in the diet equivalent or similar to OECD Guideline 414	SA 0.06, 0.1, 0.2, 0.4% (corresponding to 50.7 +/- 0.6, 77.4 +/- 1.0, 165 +/- 2.1, 205.9 +/- 18.9 mg/kg bw/d) Exposure: day 8 to 14 (daily)	NOAEL (maternal toxicity): 165 mg/kg bw/d NOAEL (developmental toxicity): 77.4 mg/kg bw/d	Tanaka S *et al.* (1973a) Klimisch score: 2 (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Prenatal developmental assay (GD 8-14) Rat (Wistar) (female) oral: gavage equivalent or similar to OECD Guideline 414	SA 75, 150, 300 mg/kg bw/d in CMC (carboxymethyl cellulose) Exposure: day 8 to 14 (daily)	NOAEL (maternal toxicity): 150 mg/kg bw/d NOAEL (developmental toxicity): 75 mg/kg bw/d	Tanaka S *et al.* (1973b) Klimisch score: 2 (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Rat (Sprague-Dawley) (17 female) subcutaneous no guideline followed Limitation: not GLP compliant	SA 380 mg/kg (nominal conc.) Vehicle: water Exposure: 2 SA administrations at 2 hr interval, on day 9, followed by mineral isotopes administration on day 9 or 16 of pregnancy Urinary excretion and foetal uptake of the	No NOAEL identified Marked maternal body weight loss, loss of appetite, complete relaxation, weakness, drowsiness, muscular limpness, inactivity, accelerated respiration rate, and occasionally elevated water intake and urinary excretion High incidence of foetal	Koshakji and Schulert (1973) Klimisch score: 3 (See Annex I of the BD for more details on the results) (See Annex II of the BD for

	mineral isotopes were measured and the foetuses were removed and inspected noting death, resorption, as well as external congenital malformations (on day 20 of gestation).	malformations and resorption, abnormally small foetuses	justification of read-across)
Data on Sodium Salicylate			
Prenatal developmental assay (GD 6-15) Rat (Sprague-Dawley) (17-19 female/dose) oral: gavage equivalent or similar to OECD Guideline 414	NaS 30, 90 or 180 mg/kg bw/d (nominal conc.) Vehicle: water Exposure: day 6 to 15 (daily)	NOAEL (embryotoxicity/ foetotoxicity): 90 mg/kg bw/d NOAEL (teratogenicity): 30 mg/kg bw/d	Fritz and Giese (1990) Klimisch score: 2 (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Rabbit (New Zealand White) (4 female) (GD 4-7) oral: gavage Limitation: few number of animals, only one concentration tested	NaS 100 mg/kg bw/d (actual ingested) Vehicle: water Exposure: day 4 to 7 (daily)	No effect on the number of implantations or on foetal development	Fabro S *et al.* (1984) Klimisch score: 3 (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Data on methyl salicylate			
Prenatal developmental assay (GD 6-18) Rabbit New Zealand White (18-20 females/group) Subcutaneous administration Study performed according to ICH guidelines and GLP	MeS (purity: 100.1%) 0, 30, 100, 300 mg/kg bw/d in corn oil Exposure: day 6 to 18 (daily)	NOAEL (development): 300 mg/kg bw/d based on no effect. NOAEL (maternal): 100 mg/kg bw/d based on abortion in one dam and on decreased body weight gain at 300 mg/kg bw/d. Increase of the plasma SA concentration nearly dependent of increases in the dose ratio and scarcely affected by repeated dosing.	FDA (2006b) Klimisch score: 1 Key study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Prenatal developmental assay (GD 6-17) Rat Crj:CD(SD)IGS (20 females/group) Subcutaneous administration Study performed according to ICH guidelines and GLP	MeS (purity: 100.1%) 0, 50, 100, 200 mg/kg bw/d in corn oil Exposure: day 6 to 17 (daily)	NOAEL (development): 100 mg/kg bw/d based on decreased body weight, external and skeletal anomalies at 200 mg/kg bw/d. NOAEL (maternal): 100 mg/kg bw/d based on depression of the body weight gain and decrease in food consumption at 200 mg/kg bw/d.	FDA (2006c) Klimisch score: 1 Key study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of

			read-across)
Study for effects on pre and postnatal development including maternal function Crj:CD(SD)IGS pregnant female rats (20/group) Subcutaneous administration. Groups of offspring sacrificed on lactation day 22 for organ weight and skeletal examination. Remaining males and females were mated to assess reproductive performance. Females sacrificed on gestation day 13. GLP and ICH guidelines	MeS (purity: 100.1%) 0, 20, 60, 200 mg/kg bw/d in corn oil Exposure: from gestation day 6 to lactation day 21	NOAEL maternal: 60 mg/kg bw/d based on decreased body weight, food consumption and mortality at 200 mg/kg bw/d. NOAEL development < 60 mg/kg bw/d based on skeletal variations at 60 mg/kg bw/d. Decreased birth index, delayed balanopreputial separation, delayed incisor eruption and skeletal anomalies and variations at 200 mg/kg bw/d.	FDA (2006d) Klimisch score: 1 Key study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 4 (offspring assessment) of the NTP continuous breeding protocol NTP protocol, GLP	MeS (purity ≥ 99%) 0, 25, 50 and 100 mg/kg bw/d. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). A second generation was then produced only for the highest dose group (task 4): the mothers were dosed through weaning and F1 mice were dosed until mated at about 74 days of age.	NOAEL (reproductive effects): 100 mg/kg bw/d – no adverse effect NOAEL (developmental effects): 100 mg/kg bw/d – no adverse effect	NTP (1984a) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Lamb *et al.*, (1997) Klimisch score: 2 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
One generation study + crossover mating study Mouse (CD-1) male/female 20/sex/dose for MeS groups and 40/sex for vehicle group. Oral: gavage in corn oil Task 2 (continuous breeding phase) & 3 (crossover mating) of the NTP continuous breeding protocol NTP protocol, GLP	MeS (purity ≥ 99%) 100, 250 and 500 mg/kg bw/d. (nominal conc.) Exposure: 7 days prior to mating, during 98 days of cohabitation (allowing the production of about 4 litters) and then during a separation period of 21 days during which final litters were delivered (task 2). Task 3: high-dose animals of each sex were mated to control mice of the opposite sex.	500 mg/kg bw/d – no effect on fertility index NOAEL (developmental effect): 100 mg/kg bw/d based on a reduction in pup weight from 250 mg/kg bw/d. At 500 mg/kg bw/d, a significant decrease in the mean number of litter and in the average of pups per litter, the proportion of pups born alive was observed. Task 3: due to fertility problem in the control groups (26% in the first task 3 and 41% in the second task 3) and lack of significant results in the litter analysis, an affected sex cannot be determined.	NTP (1984b) Chapin & Sloane (1997) Morrissey *et al.*, (1989) Klimisch score: 2 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)

Three-generation study Rat (Osborne-Mendel); male/female (20/sex/dose) Oral: feed (no vehicle) A supplementary study was performed with adding calcium carbonate to MeS diet with the same examination. Examination very limited Several deficiencies from OECD 416, not GLP	MeS 0, 500, 1500, 3000 and 5000 ppm (equivalent to 25, 75, 150, 250 mg/kg bw/d as MeS) (nominal in diet) Exposure: 100 days before the first mating and then throughout the experiment (until weaning of the 3rd generation).	NOAEL (fertility): 250 mg/kg bw/d (male/female) based on no statistically significant effect reported. NOAEL (development): 75 mg/kg bw/d based on statistically significant decrease of litter size, viability (D0), survival (D4), weaning data in the second generation and decreased pup body weight at 150 mg/kg bw/d. The addition of calcium carbonate did not markedly differ from those obtained after administration of MeS alone.	Collins TFX *et al.* (1971) Gross MA, Fitzhugh OG (1977) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Rat (Wistar) male/female 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	MeS 0.25% and 0.5% (2500 ppm and 5000 ppm equivalent to 125 and 250 mg/kg bw/d) (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (weaning of the F2b litters).	No adequate NOAEL can be set based on the low quality of the reported results. Decreased litter size at all doses. Higher number of unsuccessful matings for the first generation and decreased reproduction index for both generations at the highest dose. Higher number of death between birth and day 5 day at 250 mg/kg bw/d.	Anonymous (1978a) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
Two-generation study Mouse male/female (no data on strain); 25/sex/dose (F0); 30/sex/dose (F1) Oral: feed (no vehicle) Examination very limited Several deficiencies from OECD 416, not GLP	MeS 0.25% and 0.5% (2500 ppm and 5000 ppm, equivalent to 375 and 750 mg/kg bw/d) (nominal in diet) Exposure: 30 days before the first mating and then through the experiment (weaning of the pups).	No adequate NOAEL can be set based on the low quality of the reported results. Litter size slightly smaller in test groups only in the first generation.	Anonymous (1978b) Klimisch score: 3 Supporting study (See Annex I of the BD for more details on the results) (See Annex II of the BD for justification of read-across)
One-generation study Rat (Sprague-Dawley); male/female; 24-27 animals/dose Oral: feed (no vehicle) Guideline and GLP not stated – secondary literature	MeS 4000 ppm and 6000 ppm equivalent to 200 and 300 mg/kg bw/d (nominal in diet) Exposure: 60 days before the first mating and then throughout the experiment (until weaning of offspring on day 20-21)	NOAEL (F1): 300 mg/kg bw/d (male/female) based on no effect. No abnormalities. Neonate survival at weaning was greater in the test group than in control.	FDA (1966) CIR (2003) Klimisch score: 4 Disregarded study (See Annex II of the BD for justification of read-across)

Based on a read-across approach with SA and MeS the DS concluded that hexyl salicylate is likely to induce similar developmental effects in animals but no effects on fertility induced by

hexyl salicylate are expected. Therefore, considering the RAC opinions for the read-across substances as Repr. 2 for development, the DS proposed that hexyl salicylate should also be classified as **Repr. 2 – H361d.**

Comments received during consultation

One MS questions the read-across approach to MeS as the data do not provide any experimental evidence of the hydrolysis of hexyl salicylate in other tissues than the skin, e.g. in the liver. According to the MS, it is not possible to conclude that hydrolysis of hexyl salicylate in the body would occur as extensively as for MeS which means that it is not possible to decide if the same level of toxic effects would occur taking into account the differences in solubility and logPow between hexyl and MeS.

One industry consortium claimed that relevant data available on BzS and CHS were not considered in the CLH proposal, which do not show developmental effects in rats. Furthermore, they announced that registrants of hexyl salicylate have submitted testing proposals for an OECD TG 421/OECD TG 408 combined study and OECD TG 414 studies in two species to ECHA and that an assessment should be postponed until the new data are available.

Updated proposal by the dossier submitter for targeted consultation

In preparation of the targeted consultation, the DS proposed to use EHS as another source substance for read-across to SA and provided the following rationale.

Table: *comparative data on physico-chemical parameters and human health endpoints (modified from table 3 of AIR)*

Salicylic acid	**Sodium salicylate**	**Methyl salicylate**	**Hexyl salicylate**	**Ethylhexyl salicylate**
Classification				
Acute Tox 4 – H302 Eye Dam. 1 – H318 Repr. 2 – H361d (ATP13)	No harmonized classification	Acute Tox 4 – H302 Repr. 2 – H361d Skin Sens. 1B – H317	No harmonized classification	No harmonized classification
Water solubility				
2.17 x 10^3 mg/L at 20°C (Merck 2006)	1.25 x 10^6 mg/L in water (Merck 2006)	0.67 x 10^3 mg/L in water at ambient T (FR Sev 2021)	2 mg/L at 23°C (NL Sev 2018)	0.074 mg/L at 20°C (registration dossier)
Log P_{ow}				
2.26 (Hansch, Leo 1995)	No data	2.55 (FR Sev 2021)	5.5 (NL Sev 2018)	5.94 (registration dossier)
Vapour pressure				
8.2.10^{-5} mmHg at 25°C (Daubert, Danner 1989)	No data	10 Pa at 22°C	0.077 Pa at 23°C	0.018 Pa at 20°C

1.1 x 10^{-2} Pa at 25°C		100 Pa at 51°C (FR Sev 2021)	(NL Sev 2018)	
ADME				
- Absorption: rapid by oral route - Distribution: distributed to several organs - Metabolism: 2 major urinary metabolites, SUA and salicyl-glucuronic acid found in rats; also metabolism in a small proportion to oxidative metabolites (2,3- and 2,5-dihydroxybenzoic acid) found in rats. - Elimination: these metabolites and free unchanged SA are almost exclusively excreted in the urine. (CLH report on SA 2014)	- Absorption: rapid by oral route in rats. - Distribution: data from structurally-related salicylates (MeS) indicate wide distribution via blood and no bioaccumulation is expected after oral and dermal exposure. - Metabolism: rapid hydrolysis to free salicylate in rats. - Elimination: data from structurally-related salicylates (MeS) indicate main and rapid excretion in the urine. (CLP report on SA 2014)	- Absorption: well absorbed by oral route; oral bioavailability of 100% is assumed; very different values from 1 to 93% for dermal route; no data for inhalation exposure. - Distribution: widely distributed via blood and no bioaccumulation expected after oral and dermal administrations. - Metabolism: rapid and extensive hydrolysis to SA and methanol. After oral administration, 80% of MeS were hydrolysed in 90 minutes in humans; in dogs, hydrolysis is 95% complete in 1h and in rats, MeS is completely hydrolysed to free salicylate within 20 min. After dermal administration, free salicylate rapidly appears in blood and level of unhydrolysed MeS is low. SA obtained is then conjugated with either glycine or glucuronide and excreted inthe urine as SUA and acyl and phenolic glucuronides.	- Absorption: no data for oral and inhalation route; expected to be poorly absorbed by inhalation route based on Log P and water solubility; data are contradictory for oral route; absorption varied from 0.8% to 7.8% for dermal route for concentrations between 100 and 0.1% HS. - Distribution: data from structurally-related salicylates (MeS) indicate wide distribution via blood and no bioaccumulation is expected after oral and dermal exposure. - Metabolism: metabolism to SA by human skin esterases in an *in vitro* dermal absorption test; the QSAR Toolbox predicted the metabolites SA, hexanol, hexanal and hexanoic acid. (CLH report on hexyl salicylate 2020) QSAR modelling with Meteor and TIMES predicted hydrolysis of HS (50% in vitro)	- Absorption: well absorbed via the oral route (100% absorption assumed), low absorption via the dermal route in an *in vitro* study (3%); inhalation exposure is not relevant due to low vapour pressure. (registration dossier) - Distribution: data from structurally-related salicylates (MeS) indicate wide distribution via blood and no bioaccumulation is expected after oral and dermal exposure. - Metabolism: unchanged EHS in traces (t_R = 16.6 min) and metabolism to hydroxyl-EHS (5OH-EHS) (t_R = 12.5 min), 5oxo-EHS (t_R = 12.9 min), carboxylheptyl salicylate (cx-EHS) (t_R = 12.1 min), dinor EHS carboxylic acid metabolite, SA (t_R = 9.6 min), SUA (t_R = 8.4 min) in humans after oral exposure (Bury *et al.* 2019); also metabolism to 2-ethylhexanol (registration dossier).

		Methanol is metabolized to corresponding aldehyde and acid and ultimately to CO_2. (CLH report on MeS 2018) QSAR modelling with Meteor and TIMES predicted hydrolysis of MeS (50% in vitro) to SA and methanol (ECHA 2021) - Elimination: mainly and rapidly in the urine after oral and dermal administration; low level in the faeces. (CLH report on MeS 2018)	to SA and hexanol, hydroxylation of the alkyl chain at different sites leading to different metabolites that may be further biotransformed to SA and the corresponding alcohol (ECHA 2021). - Elimination: data from structurally-related salicylates (MeS) indicate main and rapid excretion in the urine. (CLH report on hexyl salicylate 2020)	QSAR modelling with Meteor and TIMES predicted hydrolysis of EHS (50% in vitro) to SA and 2-ethyl-1-hexanol, hydroxylation of the alkyl chain at different sites leading to different metabolites that may be further biotransformed to SA and the corresponding alcohol (ECHA 2021). - Elimination: fast excretion in the urine (peak urinary concentrations of 5OH-EHS, 5oxo-EHS and cx-EHS were found 1.6-2.6h after dose and >95% of the total amounts were excreted within 24h); it is expected that the major share of EHS dose was eliminated via urine as SA and SUA. (Bury *et al.* 2019)
Acute toxicity				
Classified as Acute Tox 4 - H302 LD_{50} oral = 400-3700 mg/kg LD_{50} dermal > 2000 mg/kg bw	LD_{50} oral = 930-1200 mg/kg LD_{50} dermal > 2000 mg/kg bw	Classified as Acute Tox 4 – H302 ATE = 580 mg/kg bw LD50 dermal > 2000 mg/kg bw	LD_{50} oral and dermal > 5000 mg/kg bw	LD_{50} oral and dermal (rat) > 5000 mg/kg bw
Acute oral toxicity of salicylates is moderate, with toxicity generally decreasing with increasing size of the alcohol moiety. Likely related to the relative proportion of SA followed hydrolysis. Methanol is of higher toxicity than the other alcohol metabolites and this is likely to explain the higher acute toxicity of MeS compared to the other salicylates.				
Repeated-dose toxicity				
No target organ reported (registration data), bones (Abbott, 1978)	Target organs: kidney and liver (registration data); bones	Target organs: bone and liver NOAELs of 50	No data available for oral route	No particular target organ reported in a OECD 421 study

	(Abbott, 1978)	mg/kg bw/d based on 2-year studies in rats and dogs (FR SeV 2021)		at doses up to 250 mg/kg bw/d (registration data)
Fertility				
No adequate study on fertility. Inhibition of human sperm mobility *in vitro* (CIR, 2003). Increased mean gestation period after treatment on GD20 & 21 in rodents (CIR, 2003).	No adequate study on fertility. Increased duration of gestation (CIR, 2003)	No effect on fertility (FDA, 2006; FR SeV 2021)	No data available	No effect on fertility (registration data)
Development				
Foetal death, growth retardation and malformations (kidney and skeletal) in rats. Classified as Repr. 2 – H361 based on experimental studies with SA, MeS, NaS and acetylsalicylic acid and on human data with acetylsalicylic acid.	Foetal death, growth retardation and malformations (mainly skeletal) in prenatal toxicity study in rats.	Lethality, external malformations, visceral/skeletal anomalies and growth retardation in rats (registration data; FDA (2006); FR SeV 2021). The lowest NOAEL for developmental toxicity can be set at < 60 mg/kg bw/d (but > 20 mg/kg bw/d) based on skeletal variations. Classified as Repr. 2 based on findings in studies in rats (malformations) and on a read-across with SA.	No data available	Increased post-implantation loss, reduction in gestation index and lower litter size in an OECD 421 study (registration data). LOAEL set by the registrants: 80 mg/kg bw/d and NOAEL: 25 mg/kg bw/d.

Studies with Ethyl Hexyl salicylate

EHS was administered once daily by gavage in corn oil as vehicle at dosages of 25, 80, and 250 mg/kg bw/d in male and female rats. Control animals received the vehicle only. Male rats were exposed for 28 days and female rats for approximately 7 weeks, i.e. 14 days prior to

pairing, through the pairing and gestation periods until the F1 generation reached day 4 post partum.

At the high dose level, one female was found dead on day 23 of the gestation period which was considered to be a result of birth complications. Slight but non-significant changes on body weight gain in female rats were also observed at this dose.

Reduction in gestation index (number of females with living pups as a percentage of females pregnant), increase in incidence of post-implantation loss resulting in a lower litter size and prolonged gestation period were observed at 80 and 250 mg/kg bw/d. Reduction in gestation index and increase in incidence of post-implantation loss were statistically significant and dose dependent effects, so these findings were considered to be test item-related adverse effects. Based on the individual data, increased post-implantation loss occurred predominantly in females with prolonged gestation. Reduction in absolute body weights of pups was observed at 250 mg/kg bw/d and was considered to be test item-related adverse effect.

Based on the observation of increased post-implantation loss, reduction in gestation index and lower litter size, the LOAEL for developmental toxicity is 80 mg/kg bw/d and the NOAEL is 25 mg/kg bw/d. The LOAEL for maternal toxicity is 250 mg/kg bw/d.

The DS concluded that developmental toxicity of EHS, and the effects reported are similar to those found with other salicylates (as MeS, NaS or SA).

QSAR studies

Furthermore, ECHA provided a QSAR analysis of the putative metabolism of salicylates using Meteor Nexus (Lhasa Ltd.) and TIMES. Meteor Nexus calculates scores for the likelihood of occurrence of metabolic reactions. The higher the yielded score, the larger the relative probability for a specific pathway to occur within the realm of predicted metabolic transformations. Based on these calculations, the DS argued that hydrolysis to SA is as probable for hexyl salicylate and ethylhexyl salicylate as it is for MeS (see table).

Table*: Probability scores for SA formation calculated with Meteor Nexus*

Biotransformation	Phase (enzyme)	MeS (MeS)	Hexyl Salicylate (HS)	Ethylhexyl salicylate (EHS)
144: Hydrolysis of acyclic carboxylic Esters	Phase I (hydrolase)	831	887, 541, 297, 463, 359, 284, 393, 300, 345	904

The DS considered the (extended) read-across plausible and proposed classification of hexyl salicylate as Repr. 2, H361d based on developmental effects seen in studies using the source substances SA, MeS, and EHS.

Comments received during targeted consultation

One MSCA considered it highly likely that the formation of SA after oral exposure would be sufficient to cause developmental toxicity *in vivo* at relevant oral dose levels.

Another MSCA accepted the read-across approach but asked for an explanation why data from ethylhexyl salicylate were considered in addition, but those from benzyl salicylate and cyclohexyl salicylate were not.

Two registrants clarified that they have submitted testing proposals for hexyl salicylate (OECD TG 421/OECD TG 408 combined study and OECD TG 414 studies in two species) to fill data gaps in the registration dossier. This would also include data on toxicokinetic analysis to determine SA exposure levels to use them as part of the reproductive toxicity risk assessment for hexyl salicylate. They also reiterated former requests to include data on cyclohexyl and benzyl salicylates in the assessment.

Assessment and comparison with the classification criteria

Read Across

RAC assessed reproductive toxicity data available for all salicylates proposed as read-across source substances for hexyl salicylate, namely SA (and NaS), MeS, EHS, CHS, and BzS. It is noted that salicylates with longer alkane chain (both linear and cyclic) or aromatic side chains have similar physico-chemical (PC) properties (e.g. solubility and Kow) as the target substance, hexyl salicylate. However, as no data are available on the possible hydrolysis of CHS or BzS (N.B. hydrolysis is the basis for the proposed read-across), RAC considered salicylates with cyclic and aromatic side chains not suitable to be used as source substances and limited the use of read-across to linear salicylates. The chemical structures, PC data and selected toxicological data for substances included in the read-across are compiled in the following table.

Substance	**Physico-chemical data**	**Reproductive toxicity data**	**Harmonised or self-classification (sc)**
Salicylic acid 	Solubility: 2.17 g/L at 20°C LogP:2.26 Vapour pressure: 0.011 Pa at 25°C)	Reprotox: Foetal death, growth retardation and **malformations** (kidney and skeletal) in rats. (similar to OECD 414)	**Repr. 2 – H361d** Acute Tox 4 – H302 Eye Dam. 1 – H318
MeS 	Solubility: 0.67 g/L LogP: 2.55 Vapour pressure: 10 Pa at 22°C	Lethality, external **malformations,** visceral/skeletal anomalies and growth retardation in rats (acc to ICH guideline)	**Repr. 2 – H361d** Acute Tox 4 – H302 Skin Sens. 1B – H317
Hexyl salicylate 	Solubility: 0.002 g/L at 23°C LogP: 5.5 Vapour pressure: 0.077 Pa at 23°C	No reproductive toxicity studies available	
Ethylhexyl salicylate 	Solubility: 0.074 mg/L at 20°C LogP: 5.94 Vapour pressure: 0.018 Pa	Increased post-implantation loss, reduction in gestation index, lower litter size at 80 and 250 mg/kg bw/d, and statistically significantly lower	Skin irrit. 2 (sc) Eye irrit. 2 (sc)

	at 20°C	mean pup body weight in rats at 250 mg/kg bw/d in OECD 421 Screening Test	

Studies with SA and MeS, are described in the proposal by the DS section.

According to the study summary of the additional reproduction / developmental toxicity screening test according to OECD guideline 421 in the registration dossier on EHS, four groups of 11 male and 11 female rats received 0, 25, 80 or 250 mg EHS per kg bw/d via gavage over a period of approximately 7 weeks, 14 to 28 days prior to mating, throughout mating and gestation periods until F1 reached day 4 postpartum. One high dose female was found dead on GD 23, considered to be a birth complication. No further effects were observed in males and females at any dose group. At 80 and 250 mg/kg bw/d a reduction in gestation index as well as an increase in incidence of post-implantation loss resulting in a lower litter size were noted. Mean number of living pups per dam were 5.3 and 9.2 at high and mid dose, respectively compared to 12 in the ctrl group. Birth index (number of pups born alive as percentage of implantations) was also reduced (42.9 % and 66.2 % at high and mid dose, respectively, vs. 88.2 % in the ctrl). No effects on litter size were noted in the low dose group. Mean number of pups was 13.1 per dam and birth index was 94.2 %. According to the registration report, these effects were statistically significant and dose dependent and therefore considered to be test item related.

During lactation, a total number of 18, 3, 10 and 13 pups (which corresponded to mean number per dam of 1.8, 0.3, 1.0 and 1.4) were lost at the dose levels of 0, 25, 80 and 250 mg/kg bw/d, respectively.

Pups sex ratio was not affected by exposure to the test item at any dose level. At the dose level of 250 mg/kg bw/d, reduced body weights of pups were noted. Mean body weights of pups were 5.0 g compared to 6.0 g in the control group (5.9 g and 6.3 g in low and mid dose group, respectively) on day 1 of the lactation period; this difference was statistically significant. Body weights of pups at the high dose level remained lower than the respective control value also on day 4 of the lactation period. Mean body weights were 7.6 g compared to 9.2 in the control group; this difference was however no longer statistically significant.

No test item related effects on body weights or body weight gain in pups were noted at the dose levels of 25 and 80 mg/kg bw/d.

Body weight gain of pups during the first four days of the lactation period was +44.4%, +42.7%, +48.0% and +44.6% in control, low, mid and high dose group, respectively.

At the mid-dose level, statistically significantly higher body weight gain was noted. In the absence of increased body weight gain at the high dose level, this was considered not to be related to the treatment with the test item.

Fertility

No animal studies nor human data are available to assess adverse effects on fertility for hexyl salicylate. No classifiable effects were noted in any of the studies on SA or MeS. Some effects were noted in the screening study with EHS. Reduced number of living pups per dam and increased post-implantation loss may be considered adverse effects on fertility. However, limited details are provided in the study summary from the registration dossier on ECHA's

dissemination website. Thus, no firm conclusion can be drawn.

Thus, RAC proposes not to classify hexyl salicylate for adverse effects on fertility due to inconclusive data.

Development

There are no human data available on developmental effects after exposure to hexyl salicylate.

Since no developmental studies are available for hexyl salicylate, the DS summarised studies on SA, NaS and MeS in their initial proposal. During targeted consultation, they added EHS to the list of substances proposed for read-across. As stated by the DS, the 2016 RAC opinion on SA and the studies listed in the above table on this substance and NaS show robust evidence of developmental effects in rats following exposure to SA. In rats, embryo-/fetotoxic effects were observed with dose dependent growth delays, foetal death and malformations without maternal toxicity.

According to the CLH report on MeS and the RAC opinion dated on September 2019 for this substance, there is clear evidence of developmental effects in two well-conducted studies in rats. Following s.c. exposure to 200 mg/kg bw/d of MeS, several developmental effects were observed. FDA 2006d reported lethality, growth retardation, external malformation, delay in post-natal differentiation indices, skeletal anomalies, skeletal variations and delay of ossification at this concentration. FDA 2006c observed significant lower foetal body weight, external malformations, visceral anomalies and skeletal variations. Although maternal toxicity also occurred at 200 mg/kg bw/d in these two studies, the observed developmental effects were not considered to be secondary to this maternal toxicity. Additionally, developmental effects were reported in fertility studies in both mice and rats (Collins *et al.* 1971, Anonymous 1978a, 1978b, NTP 1984b). It should be noted that in this case metabolic transformation to SA was experimentally shown *and* studies with MeS itself showed reproductive toxicity causing malformations and other effects. RAC used read-across to SA in their opinion on classification and labelling for MeS to justify a Repr. 2; H361d classification proposal despite clear effects in animals that could warrant a classification as Repr. 1B.

In the OECD TG 421 study with ethylhexyl salicylate, some effects were observed concerning post-implantation loss (and related mean number of pups born alive per dam) from mid dose onwards as well as on pup body weight in the highest dose group (250 mg/kg bw/d).

Conclusion on classification

According to CLP guidance version 5.0 (2017), "Substances are classified in Category 1 for reproductive toxicity when they are known to have produced an adverse effect on sexual function and fertility, or on development in humans or when there is evidence from animal studies, possibly supplemented with other information, to provide a strong presumption that the substance has the capacity to interfere with reproduction in humans. The classification of a substance is further distinguished on the basis of whether the evidence for classification is primarily from human data (Category 1A) or from animal data (Category 1B)."

Substances are classified in Category 2 for reproductive toxicity when there is some evidence from humans or experimental animals, possibly supplemented with other information, of an adverse effect on sexual function and fertility, or on development, and where the evidence is not sufficiently convincing to place the substance in Category 1. If deficiencies in the study make the quality of evidence less convincing, Category 2 could be the more appropriate

classification ("Suspected human reproductive toxicant").

Following the read-across approach using data on methyl and ethylhexyl salicylates as well as on the common metabolite SA, adopting the precautionary principle,RAC concurs with the DS and proposes classification of hexyl salicylate as **Repr. 2, H361d.**

10.8 Specific target organ toxicity-single exposure

Not assessed in this report.

10.9 Specific target organ toxicity-repeated exposure

Not assessed in this report.

10.10 Aspiration hazard

Not assessed in this report.

11 EVALUATION O ENVIRONMENTAL HAZARDS

Not assessed in this report.

12 EVALUATION OF ADDITIONAL HAZARDS

Not assessed in this report.

13 ADDITIONAL LABELLING

Not assessed in this report.

14 REFERENCES

Anonymous. 1978. Methyl salicylate: studies of osseous changes in the rat, reproduction in the rat and mouse and liver and kidney effects in the dog.

ANSM. December 2008. Test clinique final de sécurité d'un produit cosmétique en vue de confirmer son absence de potentiel sensibilisant cutané retardé : recommandations aux promoteurs de recherche et aux prestataires de service.

Bennike NH, Zachariae C, Johansenn JD. 2019. Optiman patch test concentration for three widely used sensitizing fragrance substances without mandatory labelling in cosmetics. Contact Dermatitis. 2019;80:325-327.

Chapin RE and Sloane RA. 1997. Reproductive assessment by continuous breeding: Evolving study design and summaries of ninety studies. Environ Health Perspect.;105 (S1):199-205.

CLH Report on methyl salicylate. June 2018. https://www.echa.europa.eu/web/guest/registry-of-clh-intentions-until-outcome/-/dislist/details/0b0236e182310e47

CLH Report on salicylic acid. September 2014. https://echa.europa.eu/documents/10162/5e95fc73-eb63-fdae-fa27-3849d2c99729

Collins TF, Hansen WH, Keeler HV. 1971. Effect of methyl salicylate on rat reproduction. Toxicol Appl Pharmacol.;18(4):755-65.

ANNEX 1 - BACKGROUND DOCUMENT TO RAC OPINION ON HEXYL SALICYLATE

Cosmetic Ingredients Review (CIR) Expert Panel. 2003. Safety Assessment of Salicylic Acid, Butyloctyl-, Calcium-, C12-15 Alkyl Salicylate, Capryloyl Salicylic Acid, Hexyldodecyl-, Isocetyl-, Isodecyl-, Magnesium-, MEA-, Ethylhexyl-, Potassium-, Methyl-, Myristyl-, Sodium-, TEA-, and Tridecyl Salicylate. Int J Toxico.; 22(S3):1-108.

Cosmetic Ingredient Review. May 2018. Amended safety assessment of salicylates as used in cosmetics. Re-review for panel review.

Cosmetic Ingredient Review. March 2019. Amended safety assessment of salicylic acid and salicylates as used in cosmetics. Draft final amdended report for panel review.

ECHA website: https://www.echa.europa.eu/web/guest/substance-information/-/substanceinfo/100.025.826

Fabro S, McLachlan JA, Dames NM. 1984. Chemical exposure of embryos during the preimplantation stages of pregnancy: Mortality rate and intrauterine development. Am J Obstet Gynecol 148:929-938.

FDA. 2006. Center for Drug Evaluation and Research. Pharmacology / Toxicology review and evaluation. FS-67 Patch (10% Methyl salicylate & 3% l-menthol Topical patch). NDA number 22-029. December 13, 2006

Fritz H & Giese K. 1990. Evaluation of the teratogenic potential of chemicals in the rat. Pharmacology 40 (suppl 1):1-28.

Koshakji RP and Schulert AR. 1973. Biochemical mechanisms of salicylate teratology in the rat. Biochem. Pharmacol. 22: 407-416.

Lamb J, Gulati D, Choudhury H, Chambers R, Sabharwal. 1997. Methyl salicylate. Environmental Helath Perspectives.; 105 (S1).

Lapczynski A, Jones L, McGinty D, Bhatia S, Letizia CS, Api AM. 2007. Fragrance material review on hexyl salicylate. Food Chem Toxicol.;45 (2007):S410-417. Epub 2007.

Larsen W, Nakayama H, Fischer T, Elsner P, Frosch P, Burrows D, Jordan W, Saw S, Wilkinson J, Marks J, Sugawara M, Nethercott M, Nethercott J. 2002. Fragrance contact dermatitis – a worldwide multicentre investigation (Part III). Contact Dermatitis 46, 141-144.

Morrissey RE, Lamb JC 4th, Morris RW, Chapin RE, Gulati DK, Heindel JJ. 1989. Results and evaluations of 48 continuous breeding reproduction studies conducted in mice. Fundam Appl Toxicol.;13(4):747-77.

National Toxicology Program. 1984a. Methyl salicylate: Reproduction and fertility assessment in CD-1 mice when administered by gavage. NTP, NIEHS report NTP 84-156 (PB 84-241140)

National Toxicology Program. 1984b. Methyl salicylate: Reproduction and fertility assessment in CD-1 mice when administered by gavage. NTP, NIEHS Report No. NTP-85-022, November 1984 (PB85-164283)

RAC 2016. Salicylic acid. https://www.echa.europa.eu/web/guest/registry-of-clh-intentions-until-outcome/-/dislist/details/0b0236e180653f2e

RAC 2019. Methyl salicylate. https://www.echa.europa.eu/web/guest/registry-of-clh-intentions-until-outcome/-/dislist/details/0b0236e182310e47

RIFM Expert Panel, Belsito D, Bickers D, Bruze M, Calow P, Greim H, Hanifin JM, Rogers AE, Saurat JH, Sipes IG, Tagami H. 2007. A toxicologic and dermatologic assessment of salicylates when used as fragrance ingredients. Food Chem Toxicol.;45 (S1):S318-61.

RIFM (Research Institute for Fragrance Materials Inc.), 1975b. Report on human maximization studies. RIFM report number 1798, January 31 (RIFM, Woodcliff Lake, NJ, USA).

RIFM (Research Institute for Fragrance Materials Inc.), 2004a. Repeated Insult Patch Test with Fragrance Materials. RIFM Report Number 45130, May, 3 (RIFM, Woodcliff Lake, NJ, USA).

Robert DW, Api AM, Safford RJ, Lalko JF. 2015. Regulatory Toxicology and Pharmacology 72 (2015) 683-693.

Scientific Committee on Consumer Safety (SCCS). December 2011. Opinion on Fragrance allergens in cosmetic products.

Sharp DW. 1978. The sensitization potential of some perfume ingredients tested using a modified Draize procedure. Toxicology 9, 261–271.

Substance Evaluation Report submitted by the Netherlands on hexyl salicylate. 2012. https://www.echa.europa.eu/web/guest/information-on-chemicals/evaluation/community-rolling-action-plan/corap-table/-/dislist/details/0b0236e1807e3d24

Tanaka S, Kawashima K, Nakaura S, Nagao S, Kuwamura T, Takanaka A & Omori Y. 1973a. Studies on the teratogenicity of food additives (3): Teratogenic effect of dietary salicylic acid in rats. J. Food Hyg. Soc. 14(6): 549-57.

Tanaka S, Kawashima K, Nakaura S, Nagao S, Kuwamura T, Takanaka A & Omori Y. 1973b. Studies on teratogenic effects of salicylic acid and aspirin in rats as related to fetal distribution. Departement of Pharmacology, National Institute of Hygienic Sciences, Tokyo, Japan. 13 (2): 73-84.

Unnamed. 2006. Hexyl salicylate: Local Lymph Node Assay.

Urbisch D, Mehling A, Guth K, Ramirez T, Honarvar N, Kolle S, Landsiedel R, Jaworska J, Kern PS, Gerberick F, Natsch A, Emter R, Ashikaga T, Miyazawa M, Sakaguchi H. 2015. Regulatory Toxicology and Pharmacology 71 (2015) 337-351.

Watkinson AC, Brain KR, Walters KA, Hadgraft J. 1992. Prediction of the percutaneous penetration of ultra-violet filters used in sunscreen formulations. Int J Cosmet Sci. 1992 Dec;14(6):265-75.

15 ANNEXES

ANNEX I: confidential and non-confidential annex to the CLH report (separate document)

ANNEX II: non confidential annex: rationale for read-across (separate document)

Additional references
O. Lockridge, D.M. Quinn, Esterases in Comprehensive Toxicology, 2010 (ISBN: 978-0-08-046884-6)